amiodarone has been researched along with Myocardial Infarction in 272 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to assess the association of amiodarone use with mortality during consecutive periods in patients with post-acute myocardial infarction with left ventricular systolic dysfunction and/or HF treated with a contemporary medical regimen." | 9.13 | Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. ( Al-Khatib, SM; Califf, RM; Kober, L; Lokhnygina, Y; McMurray, JJ; Solomon, SD; Thomas, KL; Velazquez, EJ, 2008) |
| " A measure of the optimum regression residual (r(opt)) has been calculated, discriminating between post-myocardial infarction patients at high and low risk of arrhythmic death while on treatment with amiodarone." | 9.11 | Characterization of QT interval adaptation to RR interval changes and its use as a risk-stratifier of arrhythmic mortality in amiodarone-treated survivors of acute myocardial infarction. ( Caminal, P; de Luna, AB; Laguna, P; Malik, M; Pueyo, E; Smetana, P, 2004) |
| "Amiodarone is an effective antiarrhythmic drug, but it has serious side effects and conducted trials did not support its prophylactic use in survivors of acute myocardial infarction." | 9.11 | Individual patterns of dynamic QT/RR relationship in survivors of acute myocardial infarction and their relationship to antiarrhythmic efficacy of amiodarone. ( Batchvarov, V; Hnatkova, K; Laguna, P; Malik, M; Pueyo, E; Smetana, P, 2004) |
| "This study was undertaken to determine the association between amiodarone therapy and risk of complications of cardiac surgery in patients in the randomized placebo-controlled, double-blind Canadian Amiodarone Myocardial Infarction Arrhythmia Trial." | 9.10 | Long-term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). ( Cairns, JA; Connolly, SJ; Crystal, E; Dorian, P; Gent, M; Kahn, S; Roberts, R; Thorpe, K, 2003) |
| "We sought to compare the long-term survival rates of patients with sustained ventricular tachyarrhythmia after myocardial infarction (MI) who were treated according to the results of electrophysiological (EP) study either with amiodarone or an implantable cardioverter-defibrillator (ICD)." | 9.10 | Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up. ( Fromer, M; Kappenberger, L; Rapp, F; Schläpfer, J, 2002) |
| "A pooled database from 2 similar randomized clinical trials, the European Amiodarone Myocardial Infarction Trial (EMIAT) and the Canadian Amiodarone Myocardial Infarction Trial (CAMIAT), was used." | 9.09 | Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. ( Boissel, JP; Boutitie, F; Cairns, JA; Camm, AJ; Connolly, SJ; Dorian, P; Frangin, G; Gent, M; Janse, MJ; Julian, DG, 1999) |
| "The objective of this study was to ascertain the effect of intravenous and oral amiodarone on morbidity and mortality in patients during the first hours after the onset of an acute myocardial infarction." | 9.09 | Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA study investigators, GEMA Group, Buenos Aires, Argentina. Grupo de Estudios Multicéntricos en Argentina. ( Belziti, C; Cagide, A; Carbajales, J; Ciruzzi, M; Elizari, MV; Garguichevich, J; Girotti, L; Martínez, JM; Pérez de la Hoz, R; Scapín, O; Sinisi, A, 2000) |
| "The European Myocardial Infarct Amiodarone Trial (EMIAT) was a randomised double-blind placebo-controlled trial to assess whether amiodarone reduced all-cause mortality (primary endpoint) and cardiac mortality and arrhythmic death (secondary endpoints) in survivors of myocardial infarction with a left-ventricular ejection fraction (LVEF) of 40% or less." | 9.08 | Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. ( Camm, AJ; Frangin, G; Janse, MJ; Julian, DG; Munoz, A; Schwartz, PJ; Simon, P, 1997) |
| "Amiodarone reduces the incidence of ventricular fibrillation or arrhythmic death among survivors of acute myocardial infarction with frequent or repetitive VPDs." | 9.08 | Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. ( Cairns, JA; Connolly, SJ; Gent, M; Roberts, R, 1997) |
| "A randomized trial was conducted to assess the efficacy of amiodarone versus metoprolol or no antiarrhythmic treatment to suppress asymptomatic ectopic activity and improve survival in patients who have had myocardial infarction with a left ventricular ejection fraction of 20 to 45% and > or = 3 ventricular premature complexes per hour (pairs or runs)." | 9.07 | Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death. ( Bayes de Luna, A; Cosin, J; Guindo, J; Marrugat, J; Navarro-López, F, 1993) |
| "The Canadian Amiodarone Myocardial Infarction Trial (CAMIAT) is a multicenter, triple-blind, randomized, placebo-controlled trial." | 9.07 | Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): rationale and protocol. CAMIAT Investigators. ( Cairns, JA; Connolly, SJ; Gent, M; Roberts, R, 1993) |
| "In the Basel Antiarrhythmic Study of Infarct Survival trial, low-dose amiodarone improved 1-year survival in patients with asymptomatic complex ventricular arrhythmias persisting 2 weeks after myocardial infarction." | 9.07 | Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. ( Brunner, H; Burckhardt, D; Burkart, F; Kiowski, W; Pfisterer, ME, 1993) |
| "In the BASIS study, an improvement in 1 year survival of patients with asymptomatic complex ventricular arrhythmias with low-dose amiodarone was shown in comparison with an untreated control group." | 9.07 | [Long-term effect of amiodarone therapy following myocardial infarct in patients with complex ventricular arrhythmias]. ( Brunner, H; Burckhardt, D; Burkart, F; Kiowski, W; Pfisterer, M, 1993) |
| "To determine whether the beneficial effect of low-dose amiodarone on survival in patients with complex ventricular arrhythmias after myocardial infarction was dependent on left ventricular (LV) function, results of the Basel Antiarrhythmic Study of Infarct Survival were analyzed." | 9.07 | Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. ( Burckhardt, D; Burkart, F; Follath, F; Kiowski, W; Pfisterer, M, 1992) |
| "Seventy-seven patients with acute myocardial infarction within the previous 6-30 days and 10 or more VPDs/hr or one or more runs of ventricular tachycardia on 24-hour electrocardiographic recording were randomized in a double-blind fashion in a 2:1 amiodarone-to-placebo ratio." | 9.07 | Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. ( Cairns, JA; Connolly, SJ; Gent, M; Roberts, R, 1991) |
| "A randomized, single-blind controlled study intended to assess the potential benefits of intravenous amiodarone in anterior myocardial infarction is presented." | 9.06 | Intravenous amiodarone in acute anterior myocardial infarction: a controlled study. ( Boccia, AS; D'Alterio, D; Greco, R; Mininni, N; Musto, B; Schiattarella, M; Wolff, S, 1989) |
| "Beta-blockers are known to be effective against post-infarction ventricular arrhythmias and amiodarone has recently been shown to have this property." | 9.06 | [Comparative efficacy of amiodarone and propranolol on ventricular arrhythmia in the post-infarction period]. ( Blondeau, M; Brunet, M; Fedorowsky, A; Fournier, C; Gensous, D; Kindermans, M; Tournadre, P, 1989) |
| "The purpose of this prospective randomized trial was to compare the efficacy of propranolol and amiodarone in suppressing ventricular arrhythmias during the first 6 months following myocardial infarction (MI)." | 9.06 | Comparison of the efficacy of propranolol and amiodarone in suppressing ventricular arrhythmias following myocardial infarction. ( Bah, M; Blondeau, M; Boujon, B; Brunet, M; Fournier, C; Giudicelli, JF; Kindermans, M; Tournadre, P, 1989) |
| "A randomized, placebo-controlled study examined the effect of amiodarone on the incidence of ventricular arrhythmias after acute myocardial infarction (AMI)." | 9.06 | Effectiveness of amiodarone on ventricular arrhythmias during and after acute myocardial infarction. ( George, T; Hajar, HA; Hockings, BE; Mahrous, F; Taylor, RR, 1987) |
| "Lidocaine (L) in still considered the drug of choice in the treatment of life threatening ventricular arrhythmias in the setting of acute myocardial infarction (A." | 9.05 | [Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction]. ( Capucci, A; Magnani, B; Mantovani, B; Maresta, A; Melandri, G, 1985) |
| "Amiodarone appears to be an effective antiarrhythmic agent for reducing mortality in the postmyocardial infarction patient with ventricular ectopic activity." | 8.79 | Use of amiodarone in the postmyocardial infarction patient. ( Carlson, TA; Massumi, A; Ozdil, E, 1995) |
| "There have been 13 randomised controlled trials of prophylactic amiodarone in patients with recent myocardial infarction (MI) or congestive heart failure (CHF)." | 8.79 | Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. ( , 1997) |
| "The prophylactic administration of amiodarone following acute myocardial infarction has been investigated in several small trials." | 8.78 | Empiric long-term amiodarone prophylaxis following myocardial infarction. A meta-analysis. ( Caruso, AC; Nolan, PE; Slack, MK; Zarembski, DG, 1993) |
| "To report a new case and review the literature of amiodarone-related epididymitis to improve knowledge of the clinical characteristics of this reaction." | 8.78 | Amiodarone-induced epididymitis: report of a new case and literature review of 12 cases. ( Biron, P; Kus, T; Sadek, I, 1993) |
| "This study aimed to investigate the effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI)." | 8.02 | Effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI). ( Li, Z; Tu, Y; Zhang, J; Zhang, M; Zhou, Q; Zong, W, 2021) |
| " The sheep were prophylactically treated with amiodarone plus lidocaine before ligation of the four to six coronary artery branches supplying the apex of the heart (arrhythmia prevention [AP] group, n = 45) and with epinephrine (shock prevention [SP] group, n = 49), respectively." | 7.79 | Prophylactic amiodarone and lidocaine improve survival in an ovine model of large size myocardial infarction. ( Griffith, BP; Li, T; Sanchez, PG; Watkins, AC; Wei, X; Wu, ZJ, 2013) |
| ") and amiodarone on the conduction system and on reverse use-dependence in the isolated hearts of normal rats and rats with myocardial infarction (MI)." | 7.78 | The effects of allitridi and amiodarone on the conduction system and reverse use-dependence in the isolated hearts of rats with myocardial infarction. ( Chen, J; Gao, Y; Guo, L; Lu, P; Niu, W; Wang, J; Wang, S; Xing, Y; Zhao, M; Zhu, H, 2012) |
| "The aim of this study is to observe the effect of combined amiodarone and antiarrhythmic peptide (AAP10) use on the incidence of induced ventricular arrhythmias in healed myocardial infarction (MI) rabbits." | 7.76 | [Effects of combined amiodarone and antiarrhythmic peptide use on the cardiac gap junctions and incidence of induced ventricular arrhythmias in healed myocardial infarction rabbit models]. ( Fang, Y; Li, LD; Ni, MK; Ruan, L; Wang, GQ; Wang, XF; Zhang, CT, 2010) |
| " In animals with postinfarction cardiosclerosis treated with amiodarone, we observed decreased accumulation of lipid peroxidation products and normalization of superoxide dismutase activity." | 7.74 | Free radical lipid peroxidation during amiodarone therapy for postinfarction cardiosclerosis. ( Afanasyev, SA; Rebrova, TY, 2008) |
| "Amiodarone-induced thyrotoxicosis is a life-threatening condition." | 7.74 | Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study. ( Ambrosini, CE; Berti, P; Bogazzi, F; Martino, E; Materazzi, G; Miccoli, P, 2007) |
| "The effects of dronedarone, a non-iodinated derivative of amiodarone, on ventricular tachycardia and ventricular fibrillation post-myocardial infarction are not well established." | 7.74 | Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats. ( Agelaki, MG; Baltogiannis, GG; Fotopoulos, A; Kolettis, TM; Korantzopoulos, P; Pantos, C; Tsalikakis, DG, 2007) |
| "This study investigated whether chronic and acute amiodarone treatment has differential effects on ventricular arrhythmogenesis during acute myocardial infarction in rats." | 7.74 | Comparative effects of acute vs. chronic oral amiodarone treatment during acute myocardial infarction in rats. ( Agelaki, MG; Baltogiannis, GG; Fotopoulos, A; Kolettis, TM; Mourouzis, I; Pantos, C; Vlahos, AP, 2007) |
| "The aim of this study was to determine whether the use of amiodarone in patients with atrial fibrillation (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker." | 7.72 | Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. ( Essebag, V; Hadjis, T; Pilote, L; Platt, RW, 2003) |
| "We examined the effect of high- (AHD) and low-dose (ALD) amiodarone on survival, hemodynamics, and left ventricular remodeling in rats with experimental myocardial infarction (MI)." | 7.72 | Effects of high- and low-dose amiodarone on mortality, left ventricular remodeling, and hemodynamics in rats with experimental myocardial infarction. ( Ertl, G; Gaudron, P; Hu, K, 2004) |
| "To determine the safety of amiodarone therapy, we conducted a retrospective analysis of elderly patients hospitalized with AMI who experienced atrial fibrillation and had survived to hospital discharge (n = 17,597)." | 7.71 | Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation. ( Gersh, BJ; Kilborn, MJ; Oetgen, WJ; Rathore, SS; Solomon, AJ, 2002) |
| "To determine the efficacy necessary to make prophylactic ICD or amiodarone therapy cost-effective in patients with myocardial infarction." | 7.71 | Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. ( Every, NR; Heidenreich, PA; Hlatky, MA; McDonald, KM; Owens, DK; Parsons, LS; Sanders, GD, 2001) |
| "Baseline characteristics of the 1486 patients enrolled in EMIAT were used to investigate the all-cause mortality effect of amiodarone (intention-to-treat) in patients with a left ventricular ejection fraction 30-40% and < 30%, in patients with and without arrhythmia signs on Holter recordings, in patients with high and low baseline resting heart rate, in patients on and off beta-blocker treatment, and in a combination of these groups." | 7.70 | Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial). ( Camm, AJ; Frangin, GA; Janse, MJ; Julian, DG; Malik, M; Schwartz, PJ, 1998) |
| "We designed a postinfarction scenario wherein heart rate variability analysis on 24-h Holter monitoring was used as a screening test for 2-year amiodarone therapy in a cohort of survivors (mean age 57 years) of a recent myocardial infarction." | 7.70 | Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction. ( Daniele, G; Mapelli, V; Migliori, GB; Pedretti, RF; Podrid, PJ; Tramarin, R, 1998) |
| "The hemodynamic and antiadrenergic effects of dronedarone, a noniodinated compound structurally related to amiodarone, were compared with those of amiodarone after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed myocardial infarction." | 7.70 | Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction. ( Djandjighian, L; Finance, O; Gautier, P; Nisato, D; Pastor, G; Planchenault, J, 2000) |
| "The aim of this study was to evaluate the efficacy of a single dose of intravenous amiodarone in facilitating defibrillation of ventricular fibrillation refractory to lidocaine and epinephrine plus direct current countershocks in experimental acute myocardial infarction." | 7.69 | Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experimental study. ( Anastasiou-Nana, MI; Moulopoulos, SD; Nanas, JN; Nanas, SN; Poyadjis, A; Rapti, A; Stathaki, S, 1994) |
| "To examine the value of programmed electrical stimulation of the heart in predicting sudden death in patients receiving amiodarone to treat ventricular tachyarrhythmias after myocardial infarction." | 7.69 | Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction. ( den Dulk, K; Oreto, G; Rodríguez, LM; Smeets, JL; Sternick, EB; Timmermans, C; Wellens, HJ, 1996) |
| "Amiodarone-induced thyrotoxicosis occurs in 2-12." | 7.69 | Ultrastructural evidence of thyroid damage in amiodarone-induced thyrotoxicosis. ( Bernasconi, R; Boldorini, R; Cappiello, E; Piraneo, S; Raggi, U; Tosoni, A, 1995) |
| "Seventy-seven consecutive patients (mean age 62 years) with episodes of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) after acute myocardial infarction (AMI) were evaluated to assess the long-term efficacy of first-line amiodarone treatment and to identify clinical and laboratory factors associated with a high risk of death or arrhythmia recurrence." | 7.68 | Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction. ( Facchin, D; Feruglio, GA; Proclemer, A; Vanuzzo, D, 1993) |
| "The antiarrhythmic effect of an 8-week oral amiodarone regimen was studied in dogs with 1-week-old myocardial infarction and reproducibly inducible sustained ventricular tachycardia (VT) or ventricular fibrillation (VF)." | 7.68 | Antiarrhythmic effect of chronic oral amiodarone treatment in dogs with myocardial infarction and reproducibly inducible sustained ventricular arrhythmias. ( Abdollah, H; Brennan, FJ; Brien, JF, 1990) |
| "The relationship between the antiarrhythmic effect of amiodarone and its myocardial concentration was studied in dogs with 1-week-old myocardial infarction and reproducibly inducible sustained ventricular tachycardia or ventricular fibrillation." | 7.68 | Relationship between myocardial amiodarone concentration and antiarrhythmic effect in dogs with myocardial infarction and electrically induced ventricular arrhythmias. ( Abdollah, H; Brennan, FJ; Brien, JF; Jimmo, S, 1991) |
| "Amiodarone in a low dose (200 mg/day) was administered alone or in combination with other type I antiarrhythmic drugs as a first-line agent in 33 patients with ventricular tachycardia (VT) (n = 24) or ventricular fibrillation (VF) (n = 9) secondary to coronary artery disease with healed myocardial infarction." | 7.68 | Long-term follow-up of postmyocardial infarction patients with ventricular tachycardia or ventricular fibrillation treated with amiodarone. ( Kusniec, J; Mager, A; Sclarovsky, S; Strasberg, B; Zlotikamien, B, 1990) |
| "Thirty-three consecutively referred patients with cardiac arrest from ventricular arrhythmias unassociated with a new acute myocardial infarction (AMI) were commenced on amiodarone therapy and followed for a minimum of 12 months." | 7.67 | Prognosis after sudden cardiac death without associated myocardial infarction: one year follow-up of empiric therapy with amiodarone. ( Hamer, A; Mandel, WJ; Peter, T; Weiss, D, 1984) |
| " To determine their relative antiarrhythmic efficacy, amiodarone and its desethyl metabolite, desethylamiodarone, were administered to mongrel dogs with ventricular tachycardia 24 hr after ligation of the left anterior descending coronary artery." | 7.67 | The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction. ( Davies, M; Nattel, S; Quantz, M, 1988) |
| "The effect of intravenous (IV) amiodarone (300 mg) on heart rate was investigated in 22 patients with acute myocardial infarction (18) or ischemia (4) and sinus tachycardia." | 7.67 | The effect of intravenous amiodarone on heart rate in patients with acute myocardial infarction or ischemia and sinus tachycardia. ( Agmon, J; Klainman, E; Kusniec, J; Sclarovsky, S; Strasberg, B, 1988) |
| "Fifty-four patients with a previous myocardial infarction and drug-refractory symptomatic ventricular tachycardia (VT) were treated with amiodarone on a long-term basis (range 6 to 54 months, mean 26) irrespective of the results of programmed ventricular stimulation, which was performed after high-dose oral amiodarone loading for more than 4 weeks." | 7.67 | Electrophysiologic predictors of long-term clinical outcome with amiodarone for refractory ventricular tachycardia secondary to coronary artery disease. ( Alpert, JS; Bishop, RL; Gold, RL; Haffajee, CI; Yazaki, Y, 1987) |
| "The autopsy tissues concentration of amiodarone and desethylamiodarone of a man with acute myocardial infarction treated acutely with intravenous amiodarone is reported." | 7.67 | Distribution of amiodarone and desethylamiodarone in a patient with acute myocardial infarction after intravenous administration. ( Barbieri, E; D'Aranno, V; Fabbri, A; Latini, R; Trevi, GP; Zampieri, P; Zardini, P, 1987) |
| "Eleven critically ill patients with life-threatening cardiac arrhythmias refractory to currently approved antiarrhythmic drugs were treated with intravenous amiodarone." | 7.67 | Intravenous amiodarone in the treatment of refractory life-threatening cardiac arrhythmias in the critically ill patient. ( Leak, D, 1986) |
| "The effect of amiodarone was investigated in a canine model of myocardial infarction." | 7.66 | Studies of amiodarone during experimental myocardial infarction: beneficial effects on hemodynamics and infarct size. ( Braunwald, E; DeBoer, LW; Kloner, RA; Nosta, JJ, 1982) |
| "Six patients are presented who developed pulmonary infiltrates of undetermined origin while being treated for severe ventricular arrhythmias with amiodarone hydrochloride." | 7.66 | Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug. ( Rakita, L; Sobol, SM, 1982) |
| "Amiodarone treatment prolonged RR intervals, reduced dispersion of action potential duration in the infarcted area and mean number of ectopic beats." | 5.51 | Amiodarone Treatment in the Early Phase of Acute Myocardial Infarction Protects Against Ventricular Fibrillation in a Porcine Model. ( Jabbari, R; Jespersen, T; Lubberding, AF; Sattler, SM; Skibsbye, L; Tfelt-Hansen, J; Wakili, R, 2019) |
| "Dronedarone has been demonstrated to be harmful in patients with recent decompensated heart failure." | 5.42 | Dronedarone does not affect infarct volume as assessed by magnetic resonance imaging in a porcine model of myocardial infarction. ( Bukowska, A; Evert, M; Goette, A; Kühn, JP; Lendeckel, U; Linke, J; Peters, B; Utpatel, K; Wolke, C, 2015) |
| "On day 21, he was complicated with acute respiratory distress syndrome." | 5.33 | Fatal case of amiodarone-induced acute respiratory distress syndrome in a patient with severe left ventricular dysfunction due to extensive anterior acute myocardial infarction. ( Ando, H; Eto, Y; Fukumoto, Y; Ikeuchi, M; Kishi, T; Kuwata, K; Nakamura, R; Okamatsu, S; Ozawa, M; Sekiya, M; Sobashima, A; Yamada, A; Yamawaki, T, 2006) |
| " The required dosage of amiodarone was lower in the D + AM group than in the AM group (603 +/- 563 mg versus 1058 +/- 680 mg, p = 0." | 5.31 | Intravenous amiodarone decreases the duration of atrial fibrillation associated with acute myocardial infarction. ( Anastasiou-Nana, MI; Kontoyannis, DA; Kontoyannis, SA; Nanas, JN; Zaga, AK, 2001) |
| "Amiodarone was effective in preventing VT recurrence." | 5.30 | Hyperkalemia probably reverses the antiarrhythmic effects of amiodarone: a case report. ( Akiyama, J; Morishima, A; Tomizawa, T; Umezawa, S, 1999) |
| "Ventricular fibrillation is a complication in patients hospitalized for acute myocardial infarction." | 5.29 | Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone. ( Bellone, P; Spirito, P; Vecchio, C, 1994) |
| "We sought to assess the association of amiodarone use with mortality during consecutive periods in patients with post-acute myocardial infarction with left ventricular systolic dysfunction and/or HF treated with a contemporary medical regimen." | 5.13 | Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. ( Al-Khatib, SM; Califf, RM; Kober, L; Lokhnygina, Y; McMurray, JJ; Solomon, SD; Thomas, KL; Velazquez, EJ, 2008) |
| "Analysing the Holter recordings collected at baseline during the European Myocardial Infarction Amiodarone Trial (EMIAT), we evaluate the possibility of using alpha, the slope of the power spectrum of heart rate variability signals (HRV) in the vicinity of f = 0, for postinfarction risk stratification." | 5.12 | HRV scaling exponent identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone. ( Cerutti, S; Hnatkova, K; Malik, M; Sassi, R; Signorini, MG, 2006) |
| " The heart rhythm was monitored continuously and ventricular arrhythmias were treated with amiodarone and cardioversion." | 5.12 | Decreased mortality in a rat model of acute postinfarction heart failure. ( Lorentzon, M; Omerovic, E; Råmunddal, T, 2006) |
| " A measure of the optimum regression residual (r(opt)) has been calculated, discriminating between post-myocardial infarction patients at high and low risk of arrhythmic death while on treatment with amiodarone." | 5.11 | Characterization of QT interval adaptation to RR interval changes and its use as a risk-stratifier of arrhythmic mortality in amiodarone-treated survivors of acute myocardial infarction. ( Caminal, P; de Luna, AB; Laguna, P; Malik, M; Pueyo, E; Smetana, P, 2004) |
| "Amiodarone is an effective antiarrhythmic drug, but it has serious side effects and conducted trials did not support its prophylactic use in survivors of acute myocardial infarction." | 5.11 | Individual patterns of dynamic QT/RR relationship in survivors of acute myocardial infarction and their relationship to antiarrhythmic efficacy of amiodarone. ( Batchvarov, V; Hnatkova, K; Laguna, P; Malik, M; Pueyo, E; Smetana, P, 2004) |
| "Perindopril was used in 287 patients with left ventricular ejection fraction < or =40% for 1 year after myocardial infarction either alone (n=53), or in combination with amiodarone (n=53), metoprolol (n=32), bisoprolol (n=32), carvedilol (n=32), atenolol (n=32), amiodarone and carvedilol (n=53)." | 5.11 | [Dynamics of postinfarction left ventricular remodeling during long term use of perindopril, amiodarone, and beta-adrenoblockers]. ( Bozhko, AA; Kanorskiĭ, SG; Staritskiĭ, AG, 2005) |
| "There was a strong trend towards lower mortality associated with the use of class I antiarrhythmic agents or sotalol in managing patients with atrial fibrillation after acute myocardial infarction." | 5.10 | Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. ( Califf, RM; Criger, DA; Ohman, EM; Topol, EJ; White, HD; Wilcox, RG; Wong, CK, 2002) |
| "This study was undertaken to determine the association between amiodarone therapy and risk of complications of cardiac surgery in patients in the randomized placebo-controlled, double-blind Canadian Amiodarone Myocardial Infarction Arrhythmia Trial." | 5.10 | Long-term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). ( Cairns, JA; Connolly, SJ; Crystal, E; Dorian, P; Gent, M; Kahn, S; Roberts, R; Thorpe, K, 2003) |
| "We sought to compare the long-term survival rates of patients with sustained ventricular tachyarrhythmia after myocardial infarction (MI) who were treated according to the results of electrophysiological (EP) study either with amiodarone or an implantable cardioverter-defibrillator (ICD)." | 5.10 | Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up. ( Fromer, M; Kappenberger, L; Rapp, F; Schläpfer, J, 2002) |
| "A pooled database from 2 similar randomized clinical trials, the European Amiodarone Myocardial Infarction Trial (EMIAT) and the Canadian Amiodarone Myocardial Infarction Trial (CAMIAT), was used." | 5.09 | Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. ( Boissel, JP; Boutitie, F; Cairns, JA; Camm, AJ; Connolly, SJ; Dorian, P; Frangin, G; Gent, M; Janse, MJ; Julian, DG, 1999) |
| "The objective of this study was to ascertain the effect of intravenous and oral amiodarone on morbidity and mortality in patients during the first hours after the onset of an acute myocardial infarction." | 5.09 | Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA study investigators, GEMA Group, Buenos Aires, Argentina. Grupo de Estudios Multicéntricos en Argentina. ( Belziti, C; Cagide, A; Carbajales, J; Ciruzzi, M; Elizari, MV; Garguichevich, J; Girotti, L; Martínez, JM; Pérez de la Hoz, R; Scapín, O; Sinisi, A, 2000) |
| "The EMIAT randomized 1,486 survivors of acute myocardial infarction (MI) aged < or =75 years with left ventricular ejection fraction (LVEF) < or =40% to amiodarone or placebo." | 5.09 | Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). ( Camm, AJ; Frangin, GA; Janse, MJ; Julian, DG; Malik, M; Schwartz, PJ, 2000) |
| "The purpose of this study was to elucidate whether the reduction of mortality with amiodarone after myocardial infarction depended on ejection fraction." | 5.08 | Lack of effect of amiodarone on survival after extensive infarction. Polish Amiodarone Trial. ( Budaj, A; Ceremuzyński, L; Dyduszyński, A; Kokowicz, P; Krzemińska-Pakuøa, M; Kuch, J; Maciejewicz, J; Nartowicz, E; Smielak-Korombel, W; Zaleska, T, 1996) |
| "The European Myocardial Infarct Amiodarone Trial (EMIAT) was a randomised double-blind placebo-controlled trial to assess whether amiodarone reduced all-cause mortality (primary endpoint) and cardiac mortality and arrhythmic death (secondary endpoints) in survivors of myocardial infarction with a left-ventricular ejection fraction (LVEF) of 40% or less." | 5.08 | Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. ( Camm, AJ; Frangin, G; Janse, MJ; Julian, DG; Munoz, A; Schwartz, PJ; Simon, P, 1997) |
| "Amiodarone reduces the incidence of ventricular fibrillation or arrhythmic death among survivors of acute myocardial infarction with frequent or repetitive VPDs." | 5.08 | Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. ( Cairns, JA; Connolly, SJ; Gent, M; Roberts, R, 1997) |
| "A randomized trial was conducted to assess the efficacy of amiodarone versus metoprolol or no antiarrhythmic treatment to suppress asymptomatic ectopic activity and improve survival in patients who have had myocardial infarction with a left ventricular ejection fraction of 20 to 45% and > or = 3 ventricular premature complexes per hour (pairs or runs)." | 5.07 | Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death. ( Bayes de Luna, A; Cosin, J; Guindo, J; Marrugat, J; Navarro-López, F, 1993) |
| "The Canadian Amiodarone Myocardial Infarction Trial (CAMIAT) is a multicenter, triple-blind, randomized, placebo-controlled trial." | 5.07 | Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): rationale and protocol. CAMIAT Investigators. ( Cairns, JA; Connolly, SJ; Gent, M; Roberts, R, 1993) |
| "The objective of the European Myocardial Infarct Amiodarone Trial (EMIAT) is to assess the efficacy of amiodarone on mortality of patients with depressed left ventricular (LV) function following myocardial infarction (MI)." | 5.07 | The European Myocardial Infarct Amiodarone Trial (EMIAT). EMIAT Investigators. ( Camm, AJ; Frangin, G; Janse, G; Julian, D; Munoz, A; Schwartz, P; Simon, P, 1993) |
| "In the Basel Antiarrhythmic Study of Infarct Survival trial, low-dose amiodarone improved 1-year survival in patients with asymptomatic complex ventricular arrhythmias persisting 2 weeks after myocardial infarction." | 5.07 | Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. ( Brunner, H; Burckhardt, D; Burkart, F; Kiowski, W; Pfisterer, ME, 1993) |
| "In the BASIS study, an improvement in 1 year survival of patients with asymptomatic complex ventricular arrhythmias with low-dose amiodarone was shown in comparison with an untreated control group." | 5.07 | [Long-term effect of amiodarone therapy following myocardial infarct in patients with complex ventricular arrhythmias]. ( Brunner, H; Burckhardt, D; Burkart, F; Kiowski, W; Pfisterer, M, 1993) |
| "To determine whether the beneficial effect of low-dose amiodarone on survival in patients with complex ventricular arrhythmias after myocardial infarction was dependent on left ventricular (LV) function, results of the Basel Antiarrhythmic Study of Infarct Survival were analyzed." | 5.07 | Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. ( Burckhardt, D; Burkart, F; Follath, F; Kiowski, W; Pfisterer, M, 1992) |
| "The EMIAT is a randomized, double-blind trial versus placebo, designed to evaluate the efficacy of amiodarone in the prevention of total mortality in patients with left ventricular ejection fraction of under 40% after myocardial infarction." | 5.07 | [Amiodarone and secondary prevention. The EMIAT study]. ( Munoz, A, 1991) |
| "Seventy-seven patients with acute myocardial infarction within the previous 6-30 days and 10 or more VPDs/hr or one or more runs of ventricular tachycardia on 24-hour electrocardiographic recording were randomized in a double-blind fashion in a 2:1 amiodarone-to-placebo ratio." | 5.07 | Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. ( Cairns, JA; Connolly, SJ; Gent, M; Roberts, R, 1991) |
| "A randomized, single-blind controlled study intended to assess the potential benefits of intravenous amiodarone in anterior myocardial infarction is presented." | 5.06 | Intravenous amiodarone in acute anterior myocardial infarction: a controlled study. ( Boccia, AS; D'Alterio, D; Greco, R; Mininni, N; Musto, B; Schiattarella, M; Wolff, S, 1989) |
| "Beta-blockers are known to be effective against post-infarction ventricular arrhythmias and amiodarone has recently been shown to have this property." | 5.06 | [Comparative efficacy of amiodarone and propranolol on ventricular arrhythmia in the post-infarction period]. ( Blondeau, M; Brunet, M; Fedorowsky, A; Fournier, C; Gensous, D; Kindermans, M; Tournadre, P, 1989) |
| "The purpose of this prospective randomized trial was to compare the efficacy of propranolol and amiodarone in suppressing ventricular arrhythmias during the first 6 months following myocardial infarction (MI)." | 5.06 | Comparison of the efficacy of propranolol and amiodarone in suppressing ventricular arrhythmias following myocardial infarction. ( Bah, M; Blondeau, M; Boujon, B; Brunet, M; Fournier, C; Giudicelli, JF; Kindermans, M; Tournadre, P, 1989) |
| "A randomized, placebo-controlled study examined the effect of amiodarone on the incidence of ventricular arrhythmias after acute myocardial infarction (AMI)." | 5.06 | Effectiveness of amiodarone on ventricular arrhythmias during and after acute myocardial infarction. ( George, T; Hajar, HA; Hockings, BE; Mahrous, F; Taylor, RR, 1987) |
| "Lidocaine (L) in still considered the drug of choice in the treatment of life threatening ventricular arrhythmias in the setting of acute myocardial infarction (A." | 5.05 | [Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction]. ( Capucci, A; Magnani, B; Mantovani, B; Maresta, A; Melandri, G, 1985) |
| " Trials that assessed whether amiodarone prophylaxis decreases the incidence of postoperative atrial tachyarrhythmias have had mixed results and were not specifically powered to detect changes in cardiovascular morbidity, length of stay, or mortality." | 4.82 | Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis. ( Aasbo, JD; Kim, MH; Krishnan, K; Lawrence, AT; Trohman, RG, 2005) |
| "Amiodarone is an antiarrhythmic agent commonly used in the treatment of supraventricular and ventricular tachyarrhythmias." | 4.80 | Amiodarone: clinical trials. ( Luck, JC; Naccarelli, GV; Patel, HM; Wolbrette, DL, 2000) |
| "Amiodarone appears to be an effective antiarrhythmic agent for reducing mortality in the postmyocardial infarction patient with ventricular ectopic activity." | 4.79 | Use of amiodarone in the postmyocardial infarction patient. ( Carlson, TA; Massumi, A; Ozdil, E, 1995) |
| " Randomized clinical trials of prophylactic amiodarone in patients with congestive heart failure and nonsustained ventricular tachycardia have produced conflicting results." | 4.79 | Evaluation and treatment of nonsustained ventricular tachycardia. ( Wilber, DJ, 1996) |
| " The trials were conducted independently from each other and both have a randomized, placebo controlled design to assess the efficacy of the class III agent amiodarone in patients with acute myocardial infarction." | 4.79 | [Anti-arrhythmia therapy after myocardial infarct: preliminary results of EMIAT and CAMIAT studies]. ( Kuck, KH, 1996) |
| "Amiodarone is useful in the treatment of patients with ventricular arrhythmias after acute myocardial infarction and was equally useful when these arrhythmias were associated with CHF." | 4.79 | Amiodarone: a late comer. ( Futterman, LG; Lemberg, L, 1997) |
| "There have been 13 randomised controlled trials of prophylactic amiodarone in patients with recent myocardial infarction (MI) or congestive heart failure (CHF)." | 4.79 | Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. ( , 1997) |
| "The prophylactic administration of amiodarone following acute myocardial infarction has been investigated in several small trials." | 4.78 | Empiric long-term amiodarone prophylaxis following myocardial infarction. A meta-analysis. ( Caruso, AC; Nolan, PE; Slack, MK; Zarembski, DG, 1993) |
| "To report a new case and review the literature of amiodarone-related epididymitis to improve knowledge of the clinical characteristics of this reaction." | 4.78 | Amiodarone-induced epididymitis: report of a new case and literature review of 12 cases. ( Biron, P; Kus, T; Sadek, I, 1993) |
| "This study aimed to investigate the effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI)." | 4.02 | Effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI). ( Li, Z; Tu, Y; Zhang, J; Zhang, M; Zhou, Q; Zong, W, 2021) |
| " The sheep were prophylactically treated with amiodarone plus lidocaine before ligation of the four to six coronary artery branches supplying the apex of the heart (arrhythmia prevention [AP] group, n = 45) and with epinephrine (shock prevention [SP] group, n = 49), respectively." | 3.79 | Prophylactic amiodarone and lidocaine improve survival in an ovine model of large size myocardial infarction. ( Griffith, BP; Li, T; Sanchez, PG; Watkins, AC; Wei, X; Wu, ZJ, 2013) |
| ") and amiodarone on the conduction system and on reverse use-dependence in the isolated hearts of normal rats and rats with myocardial infarction (MI)." | 3.78 | The effects of allitridi and amiodarone on the conduction system and reverse use-dependence in the isolated hearts of rats with myocardial infarction. ( Chen, J; Gao, Y; Guo, L; Lu, P; Niu, W; Wang, J; Wang, S; Xing, Y; Zhao, M; Zhu, H, 2012) |
| "We conducted a retrospective analysis of ST-segment elevation myocardial infarction patients with sustained ventricular tachycardia/ventricular fibrillation in Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO) IIB and GUSTO III and compared all-cause death in patients receiving amiodarone, lidocaine, or no antiarrhythmic." | 3.77 | Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. ( Alexander, JH; Ardissino, D; Califf, RM; Granger, CB; Mehta, RH; Ohman, EM; Piccini, JP; Pieper, KS; Schulte, PJ; Van de Werf, F; White, HD, 2011) |
| "The aim of this study is to observe the effect of combined amiodarone and antiarrhythmic peptide (AAP10) use on the incidence of induced ventricular arrhythmias in healed myocardial infarction (MI) rabbits." | 3.76 | [Effects of combined amiodarone and antiarrhythmic peptide use on the cardiac gap junctions and incidence of induced ventricular arrhythmias in healed myocardial infarction rabbit models]. ( Fang, Y; Li, LD; Ni, MK; Ruan, L; Wang, GQ; Wang, XF; Zhang, CT, 2010) |
| "2%) corresponding to patients in AVID where the risk was moderate and ICD/PM and amiodarone had equal efficacy, demonstrated a two-fold higher risk of sudden arrhythmic than non-arrhythmic death and hence would be expected to benefit from antiarrhythmia therapy." | 3.74 | Clinical criteria for predicting benefit of ICD/PM in post myocardial infarction patients: an AVID and CAST analysis. ( Hallstrom, AP; McAnulty, J; Wyse, DG, 2008) |
| " In animals with postinfarction cardiosclerosis treated with amiodarone, we observed decreased accumulation of lipid peroxidation products and normalization of superoxide dismutase activity." | 3.74 | Free radical lipid peroxidation during amiodarone therapy for postinfarction cardiosclerosis. ( Afanasyev, SA; Rebrova, TY, 2008) |
| "Amiodarone-induced thyrotoxicosis is a life-threatening condition." | 3.74 | Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study. ( Ambrosini, CE; Berti, P; Bogazzi, F; Martino, E; Materazzi, G; Miccoli, P, 2007) |
| "The effects of dronedarone, a non-iodinated derivative of amiodarone, on ventricular tachycardia and ventricular fibrillation post-myocardial infarction are not well established." | 3.74 | Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats. ( Agelaki, MG; Baltogiannis, GG; Fotopoulos, A; Kolettis, TM; Korantzopoulos, P; Pantos, C; Tsalikakis, DG, 2007) |
| "This study investigated whether chronic and acute amiodarone treatment has differential effects on ventricular arrhythmogenesis during acute myocardial infarction in rats." | 3.74 | Comparative effects of acute vs. chronic oral amiodarone treatment during acute myocardial infarction in rats. ( Agelaki, MG; Baltogiannis, GG; Fotopoulos, A; Kolettis, TM; Mourouzis, I; Pantos, C; Vlahos, AP, 2007) |
| "The European Myocardial Infarct Amiodarone Trial (EMIAT) investigated the effects of amiodarone versus placebo in patients after myocardial infarction who had left ventricular ejection fraction | 3.73 | Usefulness of ventricular repolarization dynamicity in predicting arrhythmic deaths in patients with ischemic cardiomyopathy (from the European Myocardial Infarct Amiodarone Trial). ( Badilini, F; Benchetrit, C; Coumel, P; Leenhardt, A; Maisonblanche, P; Milliez, P; Siliste, C; Vicaut, E, 2005) |
| " Suddenly on the 6th day of the so far uncomplicated AMI ventricular fibrillation developed and was successfully treated with DC shock, and amiodarone (150 mg i." | 3.73 | [Polymorphic ventricular tachycardia in acute myocardial infarction without ST elevation in a patient with thrombocytopenia]. ( Bromblik, A; Bryniarski, L; Czamara, M; Dragan, J; Kukla, P; Szczuka, K; Słowiak-Lewińska, T, 2006) |
| "The aim of this study was to determine whether the use of amiodarone in patients with atrial fibrillation (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker." | 3.72 | Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. ( Essebag, V; Hadjis, T; Pilote, L; Platt, RW, 2003) |
| "Comparing patients treated after myocardial infarction with amiodarone or with placebo, we found a significant rate-dependent prolongation of TpTe interval in patients who received amiodarone." | 3.72 | Effect of amiodarone on the descending limb of the T wave. ( Batchvarov, V; Camm, AJ; Hnatkova, K; Malik, M; Pueyo, E; Smetana, P, 2003) |
| "Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4." | 3.72 | [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004) |
| "Bradyarrhythmia requiring permanent pacemaker insertion has been associated with amiodarone use but the effect of amiodarone dose has not been investigated." | 3.72 | Effect of amiodarone dose on the risk of permanent pacemaker insertion. ( Abrahamowicz, M; Essebag, V; Hadjis, T; Pilote, L; Platt, RW, 2004) |
| "We examined the effect of high- (AHD) and low-dose (ALD) amiodarone on survival, hemodynamics, and left ventricular remodeling in rats with experimental myocardial infarction (MI)." | 3.72 | Effects of high- and low-dose amiodarone on mortality, left ventricular remodeling, and hemodynamics in rats with experimental myocardial infarction. ( Ertl, G; Gaudron, P; Hu, K, 2004) |
| "To determine the safety of amiodarone therapy, we conducted a retrospective analysis of elderly patients hospitalized with AMI who experienced atrial fibrillation and had survived to hospital discharge (n = 17,597)." | 3.71 | Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation. ( Gersh, BJ; Kilborn, MJ; Oetgen, WJ; Rathore, SS; Solomon, AJ, 2002) |
| "To determine the efficacy necessary to make prophylactic ICD or amiodarone therapy cost-effective in patients with myocardial infarction." | 3.71 | Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. ( Every, NR; Heidenreich, PA; Hlatky, MA; McDonald, KM; Owens, DK; Parsons, LS; Sanders, GD, 2001) |
| "Baseline characteristics of the 1486 patients enrolled in EMIAT were used to investigate the all-cause mortality effect of amiodarone (intention-to-treat) in patients with a left ventricular ejection fraction 30-40% and < 30%, in patients with and without arrhythmia signs on Holter recordings, in patients with high and low baseline resting heart rate, in patients on and off beta-blocker treatment, and in a combination of these groups." | 3.70 | Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial). ( Camm, AJ; Frangin, GA; Janse, MJ; Julian, DG; Malik, M; Schwartz, PJ, 1998) |
| "We designed a postinfarction scenario wherein heart rate variability analysis on 24-h Holter monitoring was used as a screening test for 2-year amiodarone therapy in a cohort of survivors (mean age 57 years) of a recent myocardial infarction." | 3.70 | Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction. ( Daniele, G; Mapelli, V; Migliori, GB; Pedretti, RF; Podrid, PJ; Tramarin, R, 1998) |
| "We studied the effects of dronedarone (SR 33589) on the action potentials, membrane ionic currents, and arrhythmic activity in control rats and in rats after myocardial infarction, a model known to develop anomalous electrical activity." | 3.70 | Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats. ( Aimond, F; Beck, L; Chérif, OK; Davy, JM; Gautier, P; Lorente, P; Nisato, D; Vassort, G, 2000) |
| "The hemodynamic and antiadrenergic effects of dronedarone, a noniodinated compound structurally related to amiodarone, were compared with those of amiodarone after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed myocardial infarction." | 3.70 | Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction. ( Djandjighian, L; Finance, O; Gautier, P; Nisato, D; Pastor, G; Planchenault, J, 2000) |
| "The aim of this study was to evaluate the efficacy of a single dose of intravenous amiodarone in facilitating defibrillation of ventricular fibrillation refractory to lidocaine and epinephrine plus direct current countershocks in experimental acute myocardial infarction." | 3.69 | Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experimental study. ( Anastasiou-Nana, MI; Moulopoulos, SD; Nanas, JN; Nanas, SN; Poyadjis, A; Rapti, A; Stathaki, S, 1994) |
| "To examine the value of programmed electrical stimulation of the heart in predicting sudden death in patients receiving amiodarone to treat ventricular tachyarrhythmias after myocardial infarction." | 3.69 | Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction. ( den Dulk, K; Oreto, G; Rodríguez, LM; Smeets, JL; Sternick, EB; Timmermans, C; Wellens, HJ, 1996) |
| "Amiodarone-induced thyrotoxicosis occurs in 2-12." | 3.69 | Ultrastructural evidence of thyroid damage in amiodarone-induced thyrotoxicosis. ( Bernasconi, R; Boldorini, R; Cappiello, E; Piraneo, S; Raggi, U; Tosoni, A, 1995) |
| "Seventy-seven consecutive patients (mean age 62 years) with episodes of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) after acute myocardial infarction (AMI) were evaluated to assess the long-term efficacy of first-line amiodarone treatment and to identify clinical and laboratory factors associated with a high risk of death or arrhythmia recurrence." | 3.68 | Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction. ( Facchin, D; Feruglio, GA; Proclemer, A; Vanuzzo, D, 1993) |
| "Two patients with coronary heart disease and previous myocardial infarction, treated with amiodarone for severe ventricular arrhythmias, developed pulmonary toxicity." | 3.68 | [Pulmonary toxicity due to amiodarone]. ( Ferrari, G; Galli, M; Politi, A, 1993) |
| "A potentially fatal arrhythmia was encountered in a patient with a previous myocardial infarction, who was resistant to treatment with lidocaine, amiodarone and electric defibrillation." | 3.68 | Stabilization of cardiac rhythm in subsequently fatal ventricular tachycardia and fibrillation by calcitonin gene-related peptide. ( Liu, J; Liu, XZ; Zhang, JF, 1992) |
| "A 55-year-old patient with inferior wall infarction was treated effectively for ventricular tachycardia with high-dose oral amiodarone loading regimen (5 g within 16 hours)." | 3.68 | Antiadrenergic cardiovascular adverse effects of high-dose amiodarone loading regimen. ( Frey, B; Schmidinger, H; Steurer, G, 1992) |
| "The antiarrhythmic effect of an 8-week oral amiodarone regimen was studied in dogs with 1-week-old myocardial infarction and reproducibly inducible sustained ventricular tachycardia (VT) or ventricular fibrillation (VF)." | 3.68 | Antiarrhythmic effect of chronic oral amiodarone treatment in dogs with myocardial infarction and reproducibly inducible sustained ventricular arrhythmias. ( Abdollah, H; Brennan, FJ; Brien, JF, 1990) |
| "The relationship between the antiarrhythmic effect of amiodarone and its myocardial concentration was studied in dogs with 1-week-old myocardial infarction and reproducibly inducible sustained ventricular tachycardia or ventricular fibrillation." | 3.68 | Relationship between myocardial amiodarone concentration and antiarrhythmic effect in dogs with myocardial infarction and electrically induced ventricular arrhythmias. ( Abdollah, H; Brennan, FJ; Brien, JF; Jimmo, S, 1991) |
| "Amiodarone in a low dose (200 mg/day) was administered alone or in combination with other type I antiarrhythmic drugs as a first-line agent in 33 patients with ventricular tachycardia (VT) (n = 24) or ventricular fibrillation (VF) (n = 9) secondary to coronary artery disease with healed myocardial infarction." | 3.68 | Long-term follow-up of postmyocardial infarction patients with ventricular tachycardia or ventricular fibrillation treated with amiodarone. ( Kusniec, J; Mager, A; Sclarovsky, S; Strasberg, B; Zlotikamien, B, 1990) |
| "6 mg/min for 4-40 hrs), Propafenone (1-2 mg/Kg in 5 min + continuous infusion of 10-15 mcg/Kg/min for 24 hrs) and Mexiletine (250 mg in 15 min + 250 mg in 1 hr) have been evaluated in patients with acute myocardial infarction complicated by sinus tachycardia and hyperdynamic pattern, ventricular or supraventricular arrhythmias." | 3.67 | Hemodynamic effects of antiarrhythmic drugs in acute myocardial infarction. ( Ambrosini, F; Finzi, A; Lo Masto, M; Lotto, A; Massari, FM; Pagnoni, F; Valentini, R, 1984) |
| "Thirty-three consecutively referred patients with cardiac arrest from ventricular arrhythmias unassociated with a new acute myocardial infarction (AMI) were commenced on amiodarone therapy and followed for a minimum of 12 months." | 3.67 | Prognosis after sudden cardiac death without associated myocardial infarction: one year follow-up of empiric therapy with amiodarone. ( Hamer, A; Mandel, WJ; Peter, T; Weiss, D, 1984) |
| " To determine their relative antiarrhythmic efficacy, amiodarone and its desethyl metabolite, desethylamiodarone, were administered to mongrel dogs with ventricular tachycardia 24 hr after ligation of the left anterior descending coronary artery." | 3.67 | The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction. ( Davies, M; Nattel, S; Quantz, M, 1988) |
| "The effect of intravenous (IV) amiodarone (300 mg) on heart rate was investigated in 22 patients with acute myocardial infarction (18) or ischemia (4) and sinus tachycardia." | 3.67 | The effect of intravenous amiodarone on heart rate in patients with acute myocardial infarction or ischemia and sinus tachycardia. ( Agmon, J; Klainman, E; Kusniec, J; Sclarovsky, S; Strasberg, B, 1988) |
| "Fifty-four patients with a previous myocardial infarction and drug-refractory symptomatic ventricular tachycardia (VT) were treated with amiodarone on a long-term basis (range 6 to 54 months, mean 26) irrespective of the results of programmed ventricular stimulation, which was performed after high-dose oral amiodarone loading for more than 4 weeks." | 3.67 | Electrophysiologic predictors of long-term clinical outcome with amiodarone for refractory ventricular tachycardia secondary to coronary artery disease. ( Alpert, JS; Bishop, RL; Gold, RL; Haffajee, CI; Yazaki, Y, 1987) |
| "The autopsy tissues concentration of amiodarone and desethylamiodarone of a man with acute myocardial infarction treated acutely with intravenous amiodarone is reported." | 3.67 | Distribution of amiodarone and desethylamiodarone in a patient with acute myocardial infarction after intravenous administration. ( Barbieri, E; D'Aranno, V; Fabbri, A; Latini, R; Trevi, GP; Zampieri, P; Zardini, P, 1987) |
| "Eleven critically ill patients with life-threatening cardiac arrhythmias refractory to currently approved antiarrhythmic drugs were treated with intravenous amiodarone." | 3.67 | Intravenous amiodarone in the treatment of refractory life-threatening cardiac arrhythmias in the critically ill patient. ( Leak, D, 1986) |
| "The effect of amiodarone was investigated in a canine model of myocardial infarction." | 3.66 | Studies of amiodarone during experimental myocardial infarction: beneficial effects on hemodynamics and infarct size. ( Braunwald, E; DeBoer, LW; Kloner, RA; Nosta, JJ, 1982) |
| "Six patients are presented who developed pulmonary infiltrates of undetermined origin while being treated for severe ventricular arrhythmias with amiodarone hydrochloride." | 3.66 | Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug. ( Rakita, L; Sobol, SM, 1982) |
| "Catheter ablation improves ventricular tachycardia (VT) event-free (time to event) survival in patients with antiarrhythmic drug (AAD)-refractory VT and previous myocardial infarction (MI)." | 3.30 | Ventricular Tachycardia and ICD Therapy Burden With Catheter Ablation Versus Escalated Antiarrhythmic Drug Therapy. ( Essebag, V; Gardner, M; Gray, C; Healey, JS; Hruczkowski, T; Nault, I; Parkash, R; Samuel, M; Sapp, JL; Sterns, LD, 2023) |
| "All patients enrolled in the Ventricular Tachycardia Ablation vs." | 3.11 | Ventricular tachycardia characteristics and outcomes with catheter ablation vs. antiarrhythmic therapy: insights from the VANISH trial. ( Deyell, MW; Doucette, S; Essebag, V; Gardner, M; Gray, C; Gula, L; Healey, JS; Nault, I; Parkash, R; Sapp, JL; Sterns, LD, 2022) |
| "Recurrent ventricular tachycardia among survivors of myocardial infarction with an implantable cardioverter-defibrillator (ICD) is frequent despite antiarrhythmic drug therapy." | 2.82 | Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. ( Blier, L; Essebag, V; Gula, L; Healey, JS; Leong-Sit, P; Nery, PB; Parkash, R; Raymond, JM; Redfearn, D; Rivard, L; Roux, JF; Sapp, JL; Sarrazin, JF; Sterns, LD; Stevenson, WG; Tang, AS; Thibault, B; Tung, SK; Veenhuyzen, GD; Wells, GA, 2016) |
| "IV-amiodarone was administered to 60 patients with ventricular tachyarrhythmia between 2007 and 2012." | 2.80 | Clinical and Electrocardiographic Characteristics of Electrical Storms Due to Monomorphic Ventricular Tachycardia Refractory to Intravenous Amiodarone. ( Akutsu, K; Atarashi, H; Hayashi, H; Hayashi, M; Iwasaki, YK; Katoh, T; Kobayashi, Y; Maruyama, M; Miyauchi, Y; Murata, H; Shimizu, W; Takahashi, K; Tanaka, K; Tsuboi, I; Ueno, A; Uetake, S; Yamamoto, T; Yodogawa, K, 2015) |
| "Amiodarone is a class III antiarrhythmic drug containing 37% iodine by weight, with a structure similar to that of thyroid hormones." | 2.72 | Evaluation and Treatment of Amiodarone-Induced Thyroid Disorders. ( Burman, KD; Wartofsky, L; Ylli, D, 2021) |
| "Sudden cardiac death was observed in 16 patients, 8 patients in each group." | 2.72 | Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. ( Crijns, HJ; Hagens, VE; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ, 2006) |
| "Amiodarone was judged effective in 7 patients by both tests (group I) and in 15 by either electrophysiologic study or Holter monitoring (group II)." | 2.68 | [Prediction of long-term efficacy of amiodarone for refractory ventricular tachycardia: clinical significance of electrophysiologic study and Holter monitoring]. ( Hosoda, S; Kasanuki, H; Ohnishi, S; Tsuchiya, M, 1996) |
| "Amiodarone is a potent coronary vasodilator; it has alpha and beta receptor-antagonist activity and is well-known for its marked antiarrhythmic efficacy." | 2.65 | The value of amiodarone for the treatment of unstable angina. ( Bertholet, M; Demoulin, JC; Hastir, F; Kulbertus, HE; Renier, J, 1983) |
| "The most important arrhythmia is ventricular tachycardia which degenerates to ventricular fibrillation." | 2.43 | [Strategy for cardiac arrhythmias in acute coronary syndrome]. ( Sugi, K, 2006) |
| "Amiodarone has been demonstrated to be more efficacious than propafenone or sotalol in the Canadian Trial of Atrial Fibrillation." | 2.42 | Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. ( Bhatta, L; Hynes, J; Khan, M; Luck, J; Naccarelli, GV; Samii, S; Wolbrette, DL, 2003) |
| "Sudden cardiac death is an elusive process that claims a significant number of lives annually in the United States." | 2.42 | Better living through chemistry: does it still apply to patients after myocardial infarction? ( Bobadilla, RV; Oppelt, TF, 2003) |
| "Sudden cardiac death is a prominent feature of the natural history of heart disease." | 2.41 | Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death. ( Heidenreich, PA; Hlatky, MA; Keeffe, B; McDonald, KM, 2002) |
| "Amiodarone is an antiarrhythmic agent commonly used in the treatment of supraventricular and ventricular tachyarrhythmias." | 2.41 | Amiodarone: what have we learned from clinical trials? ( Dell'Orfano, JT; Luck, JC; Naccarelli, GV; Patel, HM; Wolbrette, DL, 2000) |
| "Reports of dilated cardiomyopathy associated with Graves' disease and evidence for TSH-receptors in the human myocardium suggest a relationship between these two diseases." | 2.41 | [Hyperthyroidism and heart]. ( Weissel, M, 2001) |
| "Amiodarone is a structural analogue of thyroid hormone and some of its anti-arrhythmic properties and toxicity may be attributable to interactions with nuclear thyroid hormone receptors." | 2.41 | Amiodarone -- waxed and waned and waxed again. ( Doggrell, SA, 2001) |
| "Amiodarone was introduced as an antiarrhythmic compound in the early 1970s and was approved in the U." | 2.40 | Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. ( Singh, BN, 1997) |
| "Torsades de pointes is the classic form of proarrhythmia observed during therapy with any drug that prolongs repolarization, for example, the class III agents." | 2.40 | Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. ( Hohnloser, SH, 1997) |
| "The incidence of nonsustained ventricular tachycardia (NSVT) after myocardial infarction (MI), has decreased significantly in the thrombolytic era and may not have a high enough power to predict sudden cardiac death or all-cause mortality post-MI." | 2.40 | The role of antiarrhythmic therapy in the management of nonsustained ventricular tachycardia. ( Gomes, JA, 1999) |
| "The most important manifestation of proarrhythmia is sudden arrhythmic death." | 2.39 | What have clinical trials taught us about proarrhythmia? ( Green, MS; Skanes, AC, 1996) |
| "Patients with risk factors for sudden death, in particular those who have a severe impairment of left ventricular function and/or severe ischemia in the stress test, would be able to take advantage of a revascularization procedure when the culprit vessel remains occluded." | 2.39 | [Stratification of arrhythmia risk and therapeutic options in survivors of acute myocardial infarction]. ( Arós Borau, F; Loma-Osorio, A; Torres Bosco, A, 1996) |
| "Amiodarone is a viable drug for preventing sudden cardiac death, particularly during the first year after MI." | 2.38 | Amiodarone and post-MI patients. ( Nademanee, K; Singh, BN; Stevenson, WG; Weiss, JN, 1993) |
| "Life-threatening ventricular tachyarrhythmias are the main reason for sudden cardiac death in coronary heart disease." | 2.38 | Pharmacological therapy in coronary heart disease: prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death. ( Eggeling, T; Hombach, V; Kochs, M, 1993) |
| " It should be stressed that the drug was administered at a low dosage level (200 mg/day) to 98 patients and did not cause serious side effects." | 2.38 | Secondary prevention after myocardial infarction with class III antiarrhythmic drugs. ( Ceremuzyński, L, 1993) |
| "The Cardiac Arrhythmia Suppression Trial, which was designed to have the power to test the hypothesis that suppression of ventricular arrhythmias is associated with a decrease in mortality following myocardial infarction, even showed an increase in mortality with two drugs with class I activity." | 2.38 | [Mishaps with anti-arrhythmic agents used to reduce mortality after infarction]. ( Funck-Brentano, C, 1992) |
| " But, selenium may have toxic effects in high doses." | 1.56 | Use of an antiarrhythmic drug against acute selenium toxicity. ( Başbuğan, Y; Keleş, ÖF; Kömüroğlu, AU; Mercan Yücel, U; Uyar, A, 2020) |
| "Amiodarone treatment prolonged RR intervals, reduced dispersion of action potential duration in the infarcted area and mean number of ectopic beats." | 1.51 | Amiodarone Treatment in the Early Phase of Acute Myocardial Infarction Protects Against Ventricular Fibrillation in a Porcine Model. ( Jabbari, R; Jespersen, T; Lubberding, AF; Sattler, SM; Skibsbye, L; Tfelt-Hansen, J; Wakili, R, 2019) |
| "Polymorphic ventricular tachycardia (VT) without QT prolongation is well described in patients without structural heart disease (mainly idiopathic ventricular fibrillation and Brugada syndrome) and in patients with acute ST-elevation myocardial infarction." | 1.51 | Quinidine-Responsive Polymorphic Ventricular Tachycardia in Patients With Coronary Heart Disease. ( Amit, G; Asher, E; Belhassen, B; Chorin, E; Halkin, A; Havakuk, O; Hochstadt, A; Laish-Farkash, A; Lee, JK; Rosso, R; Tovia-Brodie, O; Viskin, D; Viskin, S, 2019) |
| "Dronedarone has been demonstrated to be harmful in patients with recent decompensated heart failure." | 1.42 | Dronedarone does not affect infarct volume as assessed by magnetic resonance imaging in a porcine model of myocardial infarction. ( Bukowska, A; Evert, M; Goette, A; Kühn, JP; Lendeckel, U; Linke, J; Peters, B; Utpatel, K; Wolke, C, 2015) |
| "Acute myocardial infarction was induced in mice (AMI), while sham operated animals served as controls (SHAM)." | 1.39 | Inhibition of thyroid hormone receptor α1 impairs post-ischemic cardiac performance after myocardial infarction in mice. ( Galanopoulos, G; Kostakou, E; Mantzouratou, P; Mourouzis, I; Pantos, C, 2013) |
| "Sheep experiencing life-threatening arrhythmias, most commonly ventricular fibrillation, were either resuscitated according to operator-driven instructions or the standardized protocol." | 1.39 | Benefits of standardizing the treatment of arrhythmias in the sheep (Ovis aries) model of chronic heart failure after myocardial infarction. ( Cheng, Y; Conditt, GB; Dardenne, A; Feeney, WP; Fernandez, C; Granada, JF; Kaluza, GL; Milewski, K; Mount, PA; Ordanes, DR; Tellez, A; Wagner, A; Yi, GH, 2013) |
| "Dronedarone is a first-line drug to prevent the recurrence of atrial fibrillation according to ESC guidelines." | 1.37 | Reduction of myocardial infarct size by dronedarone in pigs--a pleiotropic action? ( Heusch, G; Skyschally, A, 2011) |
| "We describe the case of a patient with persistent atrial fibrillation who subsequently developed an acute myocardial infarction." | 1.36 | [Acute myocardial infarction following persistent atrial fibrillation. Consequence, common etiology or a case?]. ( Bompani, B; Grassi, L; Magnavacchi, P; Ratti, C, 2010) |
| "Amiodarone was administered to groups of rats once per day for 30 days." | 1.35 | Preventive effect of amiodarone during acute period in isoproterenol-induced myocardial injury in Wistar rats. ( Albayrak, F; Bakan, E; Bayir, Y; Bayram, E; Halici, Z; Kabalar, E; Keles, MS; Kurt, M; Ozturk, C; Suleyman, H, 2009) |
| "Paroxysmal atrial fibrillation is considered a frequent complication of acute myocardial infarction and the patients with paroxysmal atrial fibrillation probably should be targeted for earlier and more aggressive treatment." | 1.35 | Conduction disturbances and paroxysmal atrial fibrillation during acute inferior myocardial infarction. ( Chiribiri, A; Di Bella, G; Marte, F; Patanè, S, 2008) |
| "For amiodarone, the IC50 was 38." | 1.33 | The influence of extracellular acidosis on the effect of IKr blockers. ( Cvetanovic, I; Ke, X; Lin, C; Ranade, V; Somberg, J, 2005) |
| "On day 21, he was complicated with acute respiratory distress syndrome." | 1.33 | Fatal case of amiodarone-induced acute respiratory distress syndrome in a patient with severe left ventricular dysfunction due to extensive anterior acute myocardial infarction. ( Ando, H; Eto, Y; Fukumoto, Y; Ikeuchi, M; Kishi, T; Kuwata, K; Nakamura, R; Okamatsu, S; Ozawa, M; Sekiya, M; Sobashima, A; Yamada, A; Yamawaki, T, 2006) |
| "The selective ablation of the recurrent ventricular tachycardia (VT) in a 75-year old patient after extensive inferior myocardial infarction (24 years ago), with low ejection fraction was performed." | 1.33 | [Eleven-years long follow-up in a patient after myocardial infarction, with low ejection fraction and recurrent ventricular tachycardia. The role of implantable cardioverter defibrillator and selective ablation]. ( Chojnowska, L; Derejko, P; Grzybowski, J; Iwanek, M; Kepski, R; Przybylski, A; Szumowski, Ł; Szwed, H; Urbanek, P; Walczak, F, 2006) |
| "Amiodarone was discontinued and the optic disc edema completely resolved over 15 months." | 1.33 | Regression of bilateral optic disc edema after discontinuation of amiodarone. ( Frohman, LP; Shinder, R; Turbin, RE, 2006) |
| " The required dosage of amiodarone was lower in the D + AM group than in the AM group (603 +/- 563 mg versus 1058 +/- 680 mg, p = 0." | 1.31 | Intravenous amiodarone decreases the duration of atrial fibrillation associated with acute myocardial infarction. ( Anastasiou-Nana, MI; Kontoyannis, DA; Kontoyannis, SA; Nanas, JN; Zaga, AK, 2001) |
| "Persistent ventricular tachycardia inducibility after catheter ablation requires an ICD implant and/or repeat ablation." | 1.31 | Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia; long-term outcome in relation to acute electrophysiological findings. ( Carbucicchio, C; De Ponti, R; Della Bella, P; Klersy, C; Longobardi, M; Riva, S; Storti, C; Tondo, C; Uriarte, JA, 2002) |
| "Hyperthyroidism is a reason for immediately suspending treatment for 90% of the cardiologists, only 5% would continue and 16% would prescribe antithyroid drugs." | 1.30 | [Amiodarone and thyroid function: clinical implications]. ( Binz, K; Burger, A; Vallotton, MB, 1998) |
| "Amiodarone was effective in preventing VT recurrence." | 1.30 | Hyperkalemia probably reverses the antiarrhythmic effects of amiodarone: a case report. ( Akiyama, J; Morishima, A; Tomizawa, T; Umezawa, S, 1999) |
| "Ventricular fibrillation is a complication in patients hospitalized for acute myocardial infarction." | 1.29 | Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone. ( Bellone, P; Spirito, P; Vecchio, C, 1994) |
| "Occurrence rates of arrhythmias treated with drugs tested for efficacy either by suppression of inducible arrhythmias or by suppression of spontaneous ectopy were higher and equivalent for both testing methods." | 1.29 | From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. ( Lazzara, R, 1996) |
| "The tachycardia was rapid (240 beats per minute) and required cardioversion." | 1.27 | Rapid ventricular tachycardia due to His-Purkinje reentry. ( Pollak, S; Walter, PF, 1984) |
| " In 17 of the 29 pts not controlled by this regimen, the dosage of A was increased to 6000-8000 mg week-1; short-term control of VT was achieved in 9/17 (53%) pts, but over a long-term follow-up 5/9 (56%) died and severe side-effects (11% pulmonary fibrosis and 11% hepatitis) occurred in 22%." | 1.27 | Medical and surgical treatment of sustained and recurrent post-infarction ventricular tachycardia. ( Bobba, P; Bressan, MA; Chimienti, M; Martinelli, L; Montemartini, C; Pagnin, A; Previtali, M; Salerno, JA; Vigano, M, 1985) |
| " Plasma pharmacokinetic profile was determined and the calculated t1/2 beta of 3." | 1.27 | Pharmacokinetics, antiarrhythmic effects, and tissue concentrations of amiodarone and desethylamiodarone in dogs with acute coronary artery occlusion. ( McManus, K; Simon, VA; Somani, P, 1985) |
| "Amiodarone was given to 17 patients with drug refractory sustained ventricular arrhythmias." | 1.27 | Amiodarone and sustained ventricular arrhythmias: statistical evidence of drug effectiveness. ( Alpert, MA; Flaker, GC; Ruder, MA; Sanfelippo, JF; Tsutakawa, RK; Webel, RR, 1985) |
| "After treatment of ischemia and/or failure, specific antiarrhythmic agents, conventional and investigational, alone or in combination, are systematically selected." | 1.26 | Ventricular ectopy: etiology, evaluation, and therapy. ( Reid, PR; Vlay, SC, 1982) |
| "Frequent ventricular arrhythmias were recorded in 58 p." | 1.26 | [Continuous ambulatory electrocardiographic recordings using the Holter system in the late phase of hospitalization for recent myocardial infarct. Value and limitations studied in a series of 100 patients]. ( Alibelli, MJ; Baradat, G; Berthoumieu, H; Constans, R; Dardenne, P; Marco, J, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 78 (28.68) | 18.7374 |
| 1990's | 96 (35.29) | 18.2507 |
| 2000's | 72 (26.47) | 29.6817 |
| 2010's | 20 (7.35) | 24.3611 |
| 2020's | 6 (2.21) | 2.80 |
| Authors | Studies |
|---|---|
| Adebesin, AM | 1 |
| Wesser, T | 1 |
| Vijaykumar, J | 1 |
| Konkel, A | 1 |
| Paudyal, MP | 1 |
| Lossie, J | 1 |
| Zhu, C | 1 |
| Westphal, C | 1 |
| Puli, N | 1 |
| Fischer, R | 1 |
| Schunck, WH | 1 |
| Falck, JR | 1 |
| Nakamura, K | 1 |
| Neidig, LE | 1 |
| Yang, X | 1 |
| Weber, GJ | 1 |
| El-Nachef, D | 1 |
| Tsuchida, H | 1 |
| Dupras, S | 1 |
| Kalucki, FA | 1 |
| Jayabalu, A | 1 |
| Futakuchi-Tsuchida, A | 1 |
| Nakamura, DS | 1 |
| Marchianò, S | 1 |
| Bertero, A | 1 |
| Robinson, MR | 1 |
| Cain, K | 1 |
| Whittington, D | 1 |
| Tian, R | 1 |
| Reinecke, H | 1 |
| Pabon, L | 1 |
| Knollmann, BC | 1 |
| Kattman, S | 1 |
| Thies, RS | 1 |
| MacLellan, WR | 1 |
| Murry, CE | 1 |
| Tu, Y | 1 |
| Zhang, J | 1 |
| Zhang, M | 1 |
| Li, Z | 1 |
| Zong, W | 1 |
| Zhou, Q | 1 |
| Deyell, MW | 1 |
| Doucette, S | 1 |
| Parkash, R | 3 |
| Nault, I | 2 |
| Gula, L | 2 |
| Gray, C | 2 |
| Gardner, M | 2 |
| Sterns, LD | 3 |
| Healey, JS | 3 |
| Essebag, V | 5 |
| Sapp, JL | 3 |
| Samuel, M | 1 |
| Hruczkowski, T | 1 |
| Mercan Yücel, U | 1 |
| Başbuğan, Y | 1 |
| Uyar, A | 1 |
| Kömüroğlu, AU | 1 |
| Keleş, ÖF | 1 |
| Ylli, D | 1 |
| Wartofsky, L | 2 |
| Burman, KD | 2 |
| Sattler, SM | 1 |
| Lubberding, AF | 1 |
| Skibsbye, L | 1 |
| Jabbari, R | 1 |
| Wakili, R | 1 |
| Jespersen, T | 1 |
| Tfelt-Hansen, J | 1 |
| Viskin, S | 1 |
| Chorin, E | 1 |
| Viskin, D | 1 |
| Hochstadt, A | 1 |
| Halkin, A | 1 |
| Tovia-Brodie, O | 1 |
| Lee, JK | 1 |
| Asher, E | 1 |
| Laish-Farkash, A | 1 |
| Amit, G | 1 |
| Havakuk, O | 1 |
| Belhassen, B | 1 |
| Rosso, R | 1 |
| Mourouzis, I | 2 |
| Kostakou, E | 1 |
| Galanopoulos, G | 1 |
| Mantzouratou, P | 1 |
| Pantos, C | 3 |
| Li, T | 1 |
| Wei, X | 1 |
| Watkins, AC | 1 |
| Sanchez, PG | 1 |
| Wu, ZJ | 1 |
| Griffith, BP | 1 |
| Dardenne, A | 1 |
| Fernandez, C | 1 |
| Wagner, A | 1 |
| Milewski, K | 1 |
| Ordanes, DR | 1 |
| Mount, PA | 1 |
| Cheng, Y | 1 |
| Yi, GH | 1 |
| Conditt, GB | 1 |
| Tellez, A | 1 |
| Kaluza, GL | 1 |
| Granada, JF | 1 |
| Feeney, WP | 1 |
| Wang, M | 1 |
| Shan, J | 1 |
| Yang, Q | 1 |
| Ma, X | 1 |
| Jin, S | 1 |
| Guo, X | 1 |
| You, Q | 1 |
| Tang, Y | 1 |
| Murata, H | 1 |
| Miyauchi, Y | 1 |
| Hayashi, M | 1 |
| Iwasaki, YK | 1 |
| Yodogawa, K | 1 |
| Ueno, A | 1 |
| Hayashi, H | 1 |
| Tsuboi, I | 1 |
| Uetake, S | 1 |
| Takahashi, K | 1 |
| Yamamoto, T | 2 |
| Maruyama, M | 1 |
| Akutsu, K | 1 |
| Kobayashi, Y | 1 |
| Tanaka, K | 1 |
| Atarashi, H | 1 |
| Katoh, T | 2 |
| Shimizu, W | 1 |
| Linke, J | 1 |
| Utpatel, K | 1 |
| Wolke, C | 1 |
| Evert, M | 1 |
| Kühn, JP | 1 |
| Bukowska, A | 1 |
| Goette, A | 1 |
| Lendeckel, U | 1 |
| Peters, B | 1 |
| Wells, GA | 1 |
| Stevenson, WG | 3 |
| Blier, L | 1 |
| Sarrazin, JF | 1 |
| Thibault, B | 1 |
| Rivard, L | 1 |
| Leong-Sit, P | 1 |
| Nery, PB | 1 |
| Tung, SK | 1 |
| Raymond, JM | 1 |
| Veenhuyzen, GD | 1 |
| Redfearn, D | 1 |
| Roux, JF | 1 |
| Tang, AS | 1 |
| Hallstrom, AP | 2 |
| Wyse, DG | 1 |
| McAnulty, J | 1 |
| Rebrova, TY | 1 |
| Afanasyev, SA | 1 |
| Dai, SM | 1 |
| Zhang, S | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Wang, FZ | 1 |
| Chen, X | 1 |
| Albayrak, F | 1 |
| Bayir, Y | 1 |
| Halici, Z | 1 |
| Kabalar, E | 1 |
| Bayram, E | 1 |
| Ozturk, C | 1 |
| Suleyman, H | 1 |
| Keles, MS | 1 |
| Kurt, M | 1 |
| Bakan, E | 1 |
| González Oliva, JC | 1 |
| Saurina i Solé, A | 1 |
| Pou Potau, M | 1 |
| Salas Gama, KR | 1 |
| Ramírez de Arellano Serna, M | 1 |
| Ratti, C | 1 |
| Grassi, L | 1 |
| Magnavacchi, P | 1 |
| Bompani, B | 1 |
| Moreno, J | 1 |
| Quintanilla, JG | 1 |
| López-Farré, A | 1 |
| Archondo, T | 1 |
| Cervigón, R | 1 |
| Aragoncillo, P | 1 |
| Usandizaga, E | 1 |
| Silva, J | 1 |
| Rodríguez-Bobada, C | 1 |
| Rojo, JL | 1 |
| Pérez-Castellano, N | 1 |
| Mironov, S | 1 |
| Mont, L | 1 |
| Pérez de Prada, T | 1 |
| Macaya, C | 1 |
| Pérez-Villacastín, J | 1 |
| Piccini, JP | 1 |
| Schulte, PJ | 1 |
| Pieper, KS | 1 |
| Mehta, RH | 1 |
| White, HD | 2 |
| Van de Werf, F | 1 |
| Ardissino, D | 1 |
| Califf, RM | 3 |
| Granger, CB | 1 |
| Ohman, EM | 2 |
| Alexander, JH | 1 |
| Auer, J | 1 |
| Lamm, G | 1 |
| Li, LD | 1 |
| Zhang, CT | 1 |
| Ruan, L | 1 |
| Ni, MK | 1 |
| Fang, Y | 1 |
| Wang, GQ | 1 |
| Wang, XF | 1 |
| Ayalloore, SG | 1 |
| LeLorier, P | 1 |
| Skyschally, A | 1 |
| Heusch, G | 1 |
| Xing, Y | 1 |
| Chen, J | 1 |
| Wang, J | 1 |
| Gao, Y | 1 |
| Niu, W | 1 |
| Zhao, M | 1 |
| Zhu, H | 1 |
| Guo, L | 1 |
| Lu, P | 1 |
| Wang, S | 1 |
| Ozturk, MA | 1 |
| Ozveren, O | 1 |
| Cinar, V | 1 |
| Erdik, B | 1 |
| Oyan, B | 1 |
| Spivack, C | 1 |
| Heidenreich, PA | 3 |
| Keeffe, B | 1 |
| McDonald, KM | 3 |
| Hlatky, MA | 4 |
| Owens, DK | 3 |
| Sanders, GD | 2 |
| Wong, CK | 1 |
| Wilcox, RG | 1 |
| Criger, DA | 1 |
| Topol, EJ | 1 |
| Knowles, S | 1 |
| Kilborn, MJ | 1 |
| Rathore, SS | 1 |
| Gersh, BJ | 1 |
| Oetgen, WJ | 1 |
| Solomon, AJ | 1 |
| Hadjis, T | 2 |
| Platt, RW | 2 |
| Pilote, L | 2 |
| Emori, T | 1 |
| Ohta, K | 1 |
| Kusano, K | 1 |
| Morita, H | 1 |
| Matsubara, H | 1 |
| Sano, S | 1 |
| Ohe, T | 1 |
| Crystal, E | 1 |
| Kahn, S | 1 |
| Roberts, R | 6 |
| Thorpe, K | 1 |
| Gent, M | 7 |
| Cairns, JA | 7 |
| Dorian, P | 4 |
| Connolly, SJ | 7 |
| Naccarelli, GV | 4 |
| Wolbrette, DL | 3 |
| Khan, M | 1 |
| Bhatta, L | 1 |
| Hynes, J | 1 |
| Samii, S | 1 |
| Luck, J | 1 |
| Moulik, PK | 1 |
| Attar, MN | 1 |
| Rose, EL | 1 |
| Khaleeli, AA | 1 |
| Oppelt, TF | 1 |
| Bobadilla, RV | 1 |
| Smetana, P | 3 |
| Pueyo, E | 3 |
| Hnatkova, K | 3 |
| Batchvarov, V | 2 |
| Camm, AJ | 11 |
| Malik, M | 8 |
| Kulasingam, SL | 1 |
| Akiyama, T | 1 |
| Mounsey, JP | 1 |
| Ledingham, R | 1 |
| Cappato, R | 1 |
| Boczor, S | 1 |
| Kuck, KH | 2 |
| Caminal, P | 1 |
| de Luna, AB | 1 |
| Laguna, P | 2 |
| Kanopskiĭ, SG | 1 |
| Staritskiĭ, AG | 2 |
| Bozhko, AA | 2 |
| Abrahamowicz, M | 1 |
| Hu, K | 1 |
| Gaudron, P | 1 |
| Ertl, G | 1 |
| Milliez, P | 1 |
| Leenhardt, A | 1 |
| Maisonblanche, P | 1 |
| Vicaut, E | 1 |
| Badilini, F | 1 |
| Siliste, C | 1 |
| Benchetrit, C | 1 |
| Coumel, P | 1 |
| Kanorskiĭ, SG | 1 |
| Lin, C | 1 |
| Ke, X | 1 |
| Cvetanovic, I | 1 |
| Ranade, V | 1 |
| Somberg, J | 1 |
| Kowey, PR | 2 |
| Bhatia, GS | 1 |
| Lip, GY | 1 |
| Aasbo, JD | 1 |
| Lawrence, AT | 1 |
| Krishnan, K | 1 |
| Kim, MH | 1 |
| Trohman, RG | 1 |
| Sassi, R | 1 |
| Cerutti, S | 1 |
| Signorini, MG | 1 |
| Råmunddal, T | 1 |
| Lorentzon, M | 1 |
| Omerovic, E | 1 |
| Sugi, K | 1 |
| Fukumoto, Y | 1 |
| Yamada, A | 1 |
| Ando, H | 1 |
| Sobashima, A | 1 |
| Kuwata, K | 1 |
| Yamawaki, T | 1 |
| Nakamura, R | 1 |
| Eto, Y | 1 |
| Kishi, T | 1 |
| Ikeuchi, M | 1 |
| Sekiya, M | 1 |
| Ozawa, M | 1 |
| Okamatsu, S | 1 |
| Serón, D | 1 |
| Hohnloser, SH | 2 |
| Israel, CW | 1 |
| Fain, E | 1 |
| Champagne, J | 1 |
| Hagège, AA | 1 |
| Marolleau, JP | 1 |
| Vilquin, JT | 1 |
| Alhéritière, A | 1 |
| Peyrard, S | 1 |
| Duboc, D | 1 |
| Abergel, E | 1 |
| Messas, E | 1 |
| Mousseaux, E | 1 |
| Schwartz, K | 1 |
| Desnos, M | 1 |
| Menasché, P | 1 |
| Przybylski, A | 1 |
| Derejko, P | 1 |
| Iwanek, M | 1 |
| Urbanek, P | 1 |
| Kepski, R | 1 |
| Grzybowski, J | 1 |
| Chojnowska, L | 1 |
| Szumowski, Ł | 1 |
| Szwed, H | 1 |
| Walczak, F | 1 |
| Bognar, Z | 1 |
| Kalai, T | 1 |
| Palfi, A | 1 |
| Hanto, K | 1 |
| Bognar, B | 1 |
| Mark, L | 1 |
| Szabo, Z | 1 |
| Tapodi, A | 1 |
| Radnai, B | 1 |
| Sarszegi, Z | 1 |
| Szanto, A | 1 |
| Gallyas, F | 1 |
| Hideg, K | 1 |
| Sumegi, B | 1 |
| Varbiro, G | 1 |
| Shinder, R | 1 |
| Frohman, LP | 1 |
| Turbin, RE | 1 |
| Russell, SJ | 1 |
| Saltissi, S | 1 |
| Hagens, VE | 1 |
| Rienstra, M | 1 |
| Van Veldhuisen, DJ | 1 |
| Crijns, HJ | 1 |
| Van Gelder, IC | 1 |
| Kukla, P | 1 |
| Bryniarski, L | 1 |
| Dragan, J | 1 |
| Słowiak-Lewińska, T | 1 |
| Czamara, M | 1 |
| Bromblik, A | 1 |
| Szczuka, K | 1 |
| Berti, P | 1 |
| Materazzi, G | 1 |
| Bogazzi, F | 1 |
| Ambrosini, CE | 1 |
| Martino, E | 1 |
| Miccoli, P | 1 |
| Agelaki, MG | 2 |
| Korantzopoulos, P | 1 |
| Tsalikakis, DG | 1 |
| Baltogiannis, GG | 2 |
| Fotopoulos, A | 2 |
| Kolettis, TM | 2 |
| Ozaydín, M | 1 |
| Varol, E | 1 |
| Dogan, A | 1 |
| Aslan, SM | 1 |
| Altínbas, A | 1 |
| Chockalingam, A | 1 |
| Tejwani, L | 1 |
| Aggarwal, K | 1 |
| Dellsperger, KC | 1 |
| Patanè, S | 1 |
| Marte, F | 1 |
| Di Bella, G | 1 |
| Chiribiri, A | 1 |
| Vlahos, AP | 1 |
| Marçon, O | 1 |
| Brembilla-Perrot, B | 1 |
| Thomas, KL | 1 |
| Al-Khatib, SM | 1 |
| Lokhnygina, Y | 1 |
| Solomon, SD | 1 |
| Kober, L | 1 |
| McMurray, JJ | 1 |
| Velazquez, EJ | 1 |
| Demoulin, JC | 2 |
| Bertholet, M | 2 |
| Chevigne, M | 1 |
| Legrand, V | 1 |
| Renier, J | 2 |
| Soumagne, D | 1 |
| Soyeur, D | 1 |
| Limet, R | 1 |
| Kulbertus, H | 1 |
| Vlay, SC | 1 |
| Reid, PR | 1 |
| Theisen, K | 2 |
| Jahrmärker, H | 1 |
| Tuna, JL | 1 |
| Correia, MJ | 2 |
| d'Almeida, VC | 1 |
| Mourão, L | 2 |
| da Costa, FL | 1 |
| Ribeiro, C | 2 |
| Yee, R | 1 |
| Klein, GJ | 1 |
| Walter, PF | 1 |
| Pollak, S | 1 |
| Gore, JM | 1 |
| Haffajee, CI | 2 |
| Alpert, JS | 2 |
| Weiss, SR | 1 |
| Lim, HW | 1 |
| Curtis, G | 1 |
| Grigor'eva, NN | 1 |
| Gichka, SG | 1 |
| Stepaniuk, GI | 1 |
| Degtiareva, LV | 1 |
| Lotto, A | 1 |
| Finzi, A | 1 |
| Massari, FM | 1 |
| Pagnoni, F | 1 |
| Valentini, R | 1 |
| Ambrosini, F | 1 |
| Lo Masto, M | 1 |
| Hastir, F | 1 |
| Kulbertus, HE | 1 |
| Patterson, E | 1 |
| Eller, BT | 1 |
| Abrams, GD | 1 |
| Vasiliades, J | 1 |
| Lucchesi, BR | 1 |
| Schrijver, G | 1 |
| Allison, SN | 1 |
| Meinders, AE | 1 |
| Chaillet, JL | 1 |
| Erba, SM | 1 |
| Puletti, M | 1 |
| Cornacchia, R | 1 |
| Curione, M | 1 |
| Borgia, C | 1 |
| Cramarossa, L | 1 |
| Petronelli, FP | 1 |
| Marrozzini, C | 1 |
| Melandri, G | 2 |
| Maresta, A | 2 |
| Magnani, B | 3 |
| Watanabe, Y | 1 |
| Burckhardt, D | 5 |
| White, RA | 1 |
| Hoffmann, A | 1 |
| Peter, T | 1 |
| Hamer, A | 1 |
| Weiss, D | 1 |
| Mandel, WJ | 1 |
| Kleĭmenova, NN | 1 |
| Kryzhanovskiĭ, SA | 1 |
| Spadaro, J | 1 |
| Hashimoto, LM | 1 |
| Franco, RS | 1 |
| Bregagnollo, EA | 1 |
| Tucci, PJ | 1 |
| Cao, J | 1 |
| Gol'dberg, GA | 1 |
| Nesterov, IuI | 1 |
| Serlin, MJ | 1 |
| Sibeon, RG | 1 |
| Green, GJ | 1 |
| Blandford, RL | 1 |
| Crampton, J | 1 |
| Kudlac, H | 1 |
| Sullivan, M | 1 |
| Barnett, DB | 1 |
| Akhtar, N | 1 |
| Hudson, SA | 1 |
| Markiewicz, M | 1 |
| Kutarski, A | 1 |
| Kudlicki, J | 1 |
| Khalfen, ESh | 1 |
| Shvarts, IL | 1 |
| Shigin, IuN | 1 |
| Klochkov, VA | 1 |
| Temkin, BM | 1 |
| Marcus, FI | 1 |
| Fontaine, GH | 1 |
| Frank, R | 1 |
| Grosgogeat, Y | 1 |
| Lukoshevichiute, AI | 1 |
| Reĭngardene, DI | 1 |
| DeBoer, LW | 1 |
| Nosta, JJ | 1 |
| Kloner, RA | 1 |
| Braunwald, E | 1 |
| Sobol, SM | 1 |
| Rakita, L | 1 |
| Ezri, MD | 1 |
| Huang, SK | 1 |
| Messer, JV | 1 |
| Denes, P | 1 |
| Stoliarchuk, AA | 1 |
| Storozhuk, BG | 1 |
| Molinis, G | 1 |
| Valente, M | 1 |
| Tuniz, D | 1 |
| Maisano, G | 1 |
| Zarembski, DG | 1 |
| Nolan, PE | 1 |
| Slack, MK | 1 |
| Caruso, AC | 1 |
| Navarro-López, F | 1 |
| Cosin, J | 1 |
| Marrugat, J | 1 |
| Guindo, J | 1 |
| Bayes de Luna, A | 1 |
| Ahmad, S | 1 |
| Nademanee, K | 2 |
| Singh, BN | 4 |
| Weiss, JN | 1 |
| Avanzini, F | 1 |
| Latini, R | 2 |
| Maggioni, A | 1 |
| Colombo, F | 1 |
| Santoro, E | 1 |
| Franzosi, MG | 1 |
| Tognoni, G | 1 |
| Seidl, K | 1 |
| Hauer, B | 1 |
| Schwick, N | 1 |
| Buechele, T | 1 |
| Schilling, I | 1 |
| Senges, J | 1 |
| Lee, HS | 1 |
| Quinn, T | 1 |
| Boyle, RM | 1 |
| Ozdil, E | 1 |
| Carlson, TA | 1 |
| Massumi, A | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Jolobe, OM | 1 |
| Schwartz, PJ | 4 |
| Frangin, G | 4 |
| Janse, MJ | 5 |
| Julian, DG | 6 |
| Simon, P | 3 |
| Bellone, P | 1 |
| Spirito, P | 1 |
| Vecchio, C | 1 |
| Kochs, M | 1 |
| Eggeling, T | 1 |
| Hombach, V | 1 |
| Ceremuzyński, L | 4 |
| Julian, D | 1 |
| Janse, G | 1 |
| Munoz, A | 3 |
| Schwartz, P | 1 |
| Proclemer, A | 1 |
| Facchin, D | 1 |
| Vanuzzo, D | 1 |
| Feruglio, GA | 1 |
| Anastasiou-Nana, MI | 2 |
| Nanas, JN | 2 |
| Nanas, SN | 1 |
| Rapti, A | 1 |
| Poyadjis, A | 1 |
| Stathaki, S | 1 |
| Moulopoulos, SD | 1 |
| Sadek, I | 1 |
| Biron, P | 1 |
| Kus, T | 1 |
| Politi, A | 1 |
| Galli, M | 1 |
| Ferrari, G | 1 |
| Pfisterer, ME | 1 |
| Kiowski, W | 4 |
| Brunner, H | 2 |
| Burkart, F | 4 |
| Pfisterer, M | 3 |
| Ducceschi, V | 1 |
| Sarubbi, B | 1 |
| Esposito, R | 1 |
| Manzo, G | 1 |
| Mayer, MS | 1 |
| Santangelo, L | 1 |
| Iacono, A | 1 |
| Sleight, P | 1 |
| Skanes, AC | 1 |
| Green, MS | 1 |
| Kautzner, J | 1 |
| Rodríguez, LM | 1 |
| Sternick, EB | 1 |
| Smeets, JL | 1 |
| Timmermans, C | 1 |
| den Dulk, K | 1 |
| Oreto, G | 1 |
| Wellens, HJ | 1 |
| Wilber, DJ | 3 |
| Arós Borau, F | 1 |
| Loma-Osorio, A | 1 |
| Torres Bosco, A | 1 |
| Ridker, PM | 1 |
| Sanderson, J | 1 |
| Kubik, L | 1 |
| Michałkiewicz, D | 1 |
| Cappiello, E | 1 |
| Boldorini, R | 1 |
| Tosoni, A | 1 |
| Piraneo, S | 1 |
| Bernasconi, R | 1 |
| Raggi, U | 1 |
| Lazzara, R | 1 |
| Budaj, A | 2 |
| Kokowicz, P | 1 |
| Smielak-Korombel, W | 1 |
| Kuch, J | 2 |
| Krzemińska-Pakuøa, M | 1 |
| Maciejewicz, J | 2 |
| Nartowicz, E | 2 |
| Zaleska, T | 2 |
| Dyduszyński, A | 2 |
| Fogoros, RN | 1 |
| Tsuchiya, M | 1 |
| Kasanuki, H | 1 |
| Ohnishi, S | 1 |
| Hosoda, S | 1 |
| Farré, J | 2 |
| Scholz, H | 1 |
| Futterman, LG | 1 |
| Lemberg, L | 1 |
| Norris, RM | 1 |
| Pinski, SL | 1 |
| Galenko-Iaroshevskiĭ, PA | 1 |
| Melkumova, ER | 1 |
| Bartashevich, VV | 1 |
| Uvarov, AV | 1 |
| Turovaia, AIu | 1 |
| Khankoeva, AI | 1 |
| Galygo, DS | 1 |
| Kall, JG | 1 |
| Kopp, DE | 1 |
| Werkö, L | 1 |
| Landray, MJ | 1 |
| Kendall, MJ | 1 |
| Frangin, GA | 2 |
| Zamorski, M | 1 |
| Pedretti, RF | 1 |
| Migliori, GB | 1 |
| Mapelli, V | 1 |
| Daniele, G | 1 |
| Podrid, PJ | 1 |
| Tramarin, R | 1 |
| Binz, K | 1 |
| Burger, A | 1 |
| Vallotton, MB | 1 |
| Prakash, VS | 1 |
| Tai, CT | 1 |
| Chen, SA | 1 |
| Romero, J | 1 |
| Rubio, JM | 1 |
| Ayala, R | 1 |
| Castro-Dorticós, J | 1 |
| Boutitie, F | 1 |
| Boissel, JP | 1 |
| Hedman, AE | 1 |
| Poloniecki, JD | 1 |
| Akiyama, J | 1 |
| Tomizawa, T | 1 |
| Umezawa, S | 1 |
| Morishima, A | 1 |
| Kausar, SA | 1 |
| Laurenzi, F | 1 |
| Avella, A | 1 |
| Adinolfi, E | 1 |
| Dini, P | 1 |
| Yap, YG | 1 |
| Aimond, F | 1 |
| Beck, L | 1 |
| Gautier, P | 2 |
| Chérif, OK | 1 |
| Davy, JM | 1 |
| Lorente, P | 1 |
| Nisato, D | 2 |
| Vassort, G | 1 |
| Scheinman, MM | 2 |
| Elizari, MV | 2 |
| Martínez, JM | 1 |
| Belziti, C | 1 |
| Ciruzzi, M | 1 |
| Pérez de la Hoz, R | 1 |
| Sinisi, A | 1 |
| Carbajales, J | 1 |
| Scapín, O | 1 |
| Garguichevich, J | 1 |
| Girotti, L | 1 |
| Cagide, A | 1 |
| Naccarella, F | 1 |
| Lepera, G | 1 |
| Rolli, A | 1 |
| Patel, HM | 2 |
| Luck, JC | 2 |
| Dell'Orfano, JT | 1 |
| Djandjighian, L | 1 |
| Planchenault, J | 1 |
| Finance, O | 1 |
| Pastor, G | 1 |
| Frankenberger, O | 1 |
| Steinberg, JS | 1 |
| Gomes, JA | 1 |
| Stiefelhagen, P | 1 |
| Weissel, M | 1 |
| Kontoyannis, DA | 1 |
| Kontoyannis, SA | 1 |
| Zaga, AK | 1 |
| Every, NR | 1 |
| Parsons, LS | 1 |
| Doggrell, SA | 1 |
| Gronda, E | 1 |
| Mangiavacchi, M | 1 |
| Andreuzzi, B | 1 |
| Municinò, A | 1 |
| Della Bella, P | 1 |
| De Ponti, R | 1 |
| Uriarte, JA | 1 |
| Tondo, C | 1 |
| Klersy, C | 1 |
| Carbucicchio, C | 1 |
| Storti, C | 1 |
| Riva, S | 1 |
| Longobardi, M | 1 |
| Lecoutre, B | 1 |
| Mabika, B | 1 |
| Derzko, G | 1 |
| Moss, AJ | 1 |
| Zareba, W | 1 |
| Hall, WJ | 1 |
| Klein, H | 1 |
| Cannom, DS | 1 |
| Daubert, JP | 1 |
| Higgins, SL | 1 |
| Brown, MW | 1 |
| Andrews, ML | 1 |
| Schläpfer, J | 1 |
| Rapp, F | 1 |
| Kappenberger, L | 1 |
| Fromer, M | 1 |
| Marco, J | 1 |
| Baradat, G | 1 |
| Constans, R | 1 |
| Alibelli, MJ | 1 |
| Berthoumieu, H | 1 |
| Dardenne, P | 1 |
| Koch-Weser, J | 1 |
| Wheeler, PJ | 1 |
| Puritz, R | 1 |
| Ingram, DV | 1 |
| Chamberlain, DA | 1 |
| Guibradze, T | 1 |
| Kobaladze, S | 1 |
| Isakadze, A | 1 |
| Casillas Ruíz, JA | 1 |
| Fernández Berridi, D | 1 |
| Malpartida de Torres, F | 1 |
| Quintanilla Gutiérrez, E | 1 |
| Greco, R | 2 |
| Musto, B | 2 |
| De Martino, U | 1 |
| Marsico, F | 1 |
| Girotti, AL | 1 |
| Halpern, MS | 1 |
| Rosenbaum, MB | 1 |
| Funck-Brentano, C | 1 |
| Kleczar, E | 1 |
| Krzeminska-Pakula, M | 1 |
| Smielak-Korombel, J | 1 |
| Lazarczyk-Kedzia, E | 1 |
| Bach, P | 1 |
| Gonschior, P | 1 |
| Prinz, C | 1 |
| Kreuzer, E | 1 |
| Autenrieth, G | 1 |
| Steinbeck, G | 1 |
| Zhang, JF | 1 |
| Liu, J | 1 |
| Liu, XZ | 1 |
| Steurer, G | 1 |
| Schmidinger, H | 1 |
| Frey, B | 1 |
| Follath, F | 2 |
| Abdollah, H | 3 |
| Brien, JF | 3 |
| Brennan, FJ | 3 |
| Winslow, E | 1 |
| Campbell, JK | 1 |
| Barron, E | 1 |
| Ware, WA | 1 |
| Muir, WW | 1 |
| Swanson, C | 1 |
| Jimmo, S | 1 |
| Wolfe, CL | 1 |
| Nibley, C | 1 |
| Bhandari, A | 1 |
| Chatterjee, K | 1 |
| Scheinman, M | 1 |
| Rogers, JG | 1 |
| Windle, JR | 1 |
| McManus, BM | 1 |
| Easley, AR | 1 |
| Keung, EC | 1 |
| Strasberg, B | 2 |
| Kusniec, J | 2 |
| Zlotikamien, B | 1 |
| Mager, A | 1 |
| Sclarovsky, S | 2 |
| Roden, DM | 1 |
| Oleĭnikov, VE | 1 |
| Tatarchenko, IP | 1 |
| Zhivotovskaia, GG | 1 |
| Nattel, S | 1 |
| Davies, M | 1 |
| Quantz, M | 1 |
| Suárez Ortega, S | 1 |
| Franco Cebrián, J | 1 |
| Medina Fernández-Aceytuno, A | 1 |
| Armas Portela, M | 1 |
| Méndez Mora, D | 1 |
| Estévez Zarazaga, A | 1 |
| Marinchak, RA | 1 |
| O'Connor, KM | 1 |
| Friehling, TD | 1 |
| Dobrotvorskaia, TE | 1 |
| Mustafaev, FM | 1 |
| Abdullaeva, TI | 1 |
| Matsueva, NL | 1 |
| D'Alterio, D | 1 |
| Schiattarella, M | 1 |
| Wolff, S | 1 |
| Boccia, AS | 1 |
| Mininni, N | 1 |
| Fournier, C | 2 |
| Brunet, M | 2 |
| Kindermans, M | 2 |
| Fedorowsky, A | 1 |
| Tournadre, P | 2 |
| Gensous, D | 1 |
| Blondeau, M | 2 |
| Aomine, M | 1 |
| Bah, M | 1 |
| Boujon, B | 1 |
| Giudicelli, JF | 1 |
| Anderson, JL | 1 |
| Cherevatov, BG | 1 |
| Kucherenko, OD | 1 |
| Ovcharenko, LI | 1 |
| Shelest, AN | 1 |
| Monteiro, E | 1 |
| Galvão-teles, A | 1 |
| Santos, ML | 1 |
| Lopo Tuna, J | 1 |
| Brown, AK | 1 |
| Holt, DW | 1 |
| Anderson, V | 1 |
| Cowan, JC | 1 |
| Gardiner, P | 1 |
| Reid, DS | 1 |
| Newell, DJ | 1 |
| Campbell, RW | 1 |
| Dłuzniewski, M | 1 |
| Jurgiel, R | 1 |
| Bednarz, B | 1 |
| Grochowicz, U | 1 |
| Gebalska, J | 1 |
| Kłoś, K | 1 |
| Klainman, E | 1 |
| Agmon, J | 1 |
| Capucci, A | 2 |
| Boriani, G | 1 |
| Balducelli, M | 1 |
| Kheĭnonen, IM | 1 |
| Semikhatova, OB | 1 |
| Aretinskiĭ, VV | 1 |
| Shepherd, NA | 1 |
| Dawson, AM | 1 |
| Crocker, PR | 1 |
| Levison, DA | 1 |
| Yazaki, Y | 1 |
| Gold, RL | 1 |
| Bishop, RL | 1 |
| Hockings, BE | 1 |
| George, T | 1 |
| Mahrous, F | 1 |
| Taylor, RR | 1 |
| Hajar, HA | 1 |
| Barbieri, E | 1 |
| D'Aranno, V | 1 |
| Fabbri, A | 1 |
| Zampieri, P | 1 |
| Trevi, GP | 1 |
| Zardini, P | 1 |
| Nguyen, PT | 1 |
| Seger, J | 1 |
| Ericson, T | 1 |
| Mogensen, L | 1 |
| Rotstein, Z | 1 |
| Schneeweiss, A | 1 |
| Shotan, A | 1 |
| Har-Zahav, Y | 1 |
| Rath, S | 1 |
| Battler, A | 1 |
| Neufeld, HN | 1 |
| Salerno, JA | 1 |
| Bressan, MA | 1 |
| Vigano, M | 1 |
| Chimienti, M | 1 |
| Previtali, M | 1 |
| Martinelli, L | 1 |
| Pagnin, A | 1 |
| Montemartini, C | 1 |
| Bobba, P | 1 |
| Somani, P | 1 |
| Simon, VA | 1 |
| McManus, K | 1 |
| Leak, D | 1 |
| Vergara, G | 1 |
| Disertori, M | 1 |
| Inama, G | 1 |
| Guarnerio, M | 1 |
| Bettini, R | 1 |
| Stirpe, E | 1 |
| Furlanello, F | 1 |
| Mantovani, B | 1 |
| Flaker, GC | 1 |
| Alpert, MA | 1 |
| Webel, RR | 1 |
| Ruder, MA | 1 |
| Sanfelippo, JF | 1 |
| Tsutakawa, RK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Endocardial-Epicardial Radiofrequency Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy[NCT04512911] | Early Phase 1 | 0 participants (Actual) | Interventional | 2023-01-31 | Withdrawn (stopped due to IRB approval expired 1/23/2023 and eclipsed the 6 month institutional window where study can be reinitiated via progress report. No enrollment has taken place.) | ||
| STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease[NCT03819504] | 0 participants (Actual) | Interventional | 2018-08-01 | Withdrawn (stopped due to Change in the design of the study) | |||
| Phase I/II Study of 4-D Navigated Non-invasive Radiosurgical Ablation of Ventricular Tachycardia[NCT03601832] | 10 participants (Actual) | Interventional | 2018-08-01 | Completed | |||
| VOYAGE- Ventricular Tachycardia Ablation and Myocardial Scar Characterization With Magnetic Resonance[NCT04694079] | Phase 3 | 103 participants (Anticipated) | Interventional | 2020-08-03 | Recruiting | ||
| STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease[NCT04612140] | 100 participants (Actual) | Interventional | 2020-10-01 | Completed | |||
| Ventricular Tachycardia Ablation or Escalated aNtiarrhythmic Drugs in ISchemic Heart Disease[NCT00905853] | Phase 4 | 260 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Repeated Endocardial Mapping for Efficacy Assessment After Catheter Ablation for Ischemic Ventricular Tachycardia[NCT05713357] | 20 participants (Anticipated) | Observational | 2023-03-15 | Enrolling by invitation | |||
| Initial Management of Patients Receiving a Single Shock (IMPRESS)[NCT03531502] | 30 participants (Actual) | Interventional | 2018-04-09 | Terminated (stopped due to lack of funding) | |||
| Preventive VT Substrate Ablation in Patients With Chronic Post-MI Scar Showing Arrhythmogenic Characteristics[NCT04675073] | Phase 3 | 58 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | ||
| ECG Device for Long QT Syndrome Screening in Newborns[NCT02412709] | Phase 2 | 4,000 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| aMsa and amiOdarone Study in cArdiaC Arrest[NCT04997980] | 500 participants (Anticipated) | Observational | 2015-01-01 | Recruiting | |||
| [NCT00257959] | Phase 4 | 400 participants | Interventional | 2001-01-31 | Completed | ||
| Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2021-10-29 | Active, not recruiting | ||
| Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534] | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to No enrollment in study.) | |||
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)[NCT02026102] | 15 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart[NCT00326690] | 0 participants (Actual) | Interventional | 2005-11-30 | Withdrawn (stopped due to Unable to recruit and enroll patients) | |||
| Arrhythmia Prediction Trial and Risk Stratification in Heart Failure Patients - Athens.[NCT02175836] | 500 participants (Anticipated) | Observational | 2007-10-31 | Recruiting | |||
| CMR Based Prediction of Ventricular Tachycardia Events in Healed Myocardial Infarction (DEVELOP-VT)[NCT04599439] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2020-08-01 | Recruiting | |||
| An Intervention to Improve ICD Deactivation Conversations (WISDOM - Working to Improve discuSsions About DefibrillatOr Management)[NCT01459744] | 562 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| Effects of Surgical Monopolar Electrocautery and Optimal Electrosurgery Unit Return Pad Placement on Implantable Cardioverter Defibrillators Protocol[NCT01572246] | 167 participants (Actual) | Observational | 2012-05-31 | Completed | |||
| Nursing Therapeutics Education and Heart Failure (HF): an Experimental Study[NCT02425488] | 30 participants (Actual) | Interventional | 2015-04-30 | Terminated (stopped due to Feasability phase completed: Cost Evaluation) | |||
| Non-invasive Programmed Stimulation to Identify High-risk Patients With Implanted Cardioverter-defibrillator[NCT02373306] | 150 participants (Anticipated) | Interventional | 2013-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
51 reviews available for amiodarone and Myocardial Infarction
| Article | Year |
|---|---|
Evaluation and Treatment of Amiodarone-Induced Thyroid Disorders.
Topics: Albania; Amiodarone; Arrhythmias, Cardiac; Coronary Artery Disease; Humans; Male; Middle Aged; Myoca | 2021 |
Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2013 |
Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Femal | 2002 |
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Canada; Controlled Clinical Tria | 2003 |
Better living through chemistry: does it still apply to patients after myocardial infarction?
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Ag | 2003 |
A review of carvedilol arrhythmia data in clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca | 2005 |
Atrial fibrillation post-myocardial infarction: frequency, consequences, and management.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Heart Failure; | 2004 |
Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardi | 2005 |
[Strategy for cardiac arrhythmias in acute coronary syndrome].
Topics: Amiodarone; Angina, Unstable; Anti-Asthmatic Agents; Aprindine; Atrial Fibrillation; Bepridil; Elect | 2006 |
Dynamic left ventricular outflow tract obstruction in acute myocardial infarction with shock: cause, effect, and coincidence.
Topics: Adrenergic beta-Antagonists; Aged; Algorithms; Amiodarone; Cardiac Catheterization; Diagnosis, Diffe | 2007 |
[Medical treatment of extrasystole and tachycardia (author's transl)].
Topics: Action Potentials; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Bretylium Compounds; Calcium; Cardi | 1980 |
Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome".
Topics: Adult; Age Factors; Aged; Amiodarone; Animals; Anorexia Nervosa; Contrast Media; Diabetes Mellitus; | 1982 |
Clinical pharmacology and therapeutic applications of the antiarrhythmic agent amiodarone.
Topics: Acute Disease; Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atria | 1981 |
[Value of drug tests in Wolff-Parkinson-White syndrome].
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrioventricular Node; Diagnosis, Differential; Electr | 1981 |
Empiric long-term amiodarone prophylaxis following myocardial infarction. A meta-analysis.
Topics: Aged; Amiodarone; Cardiac Complexes, Premature; Death, Sudden, Cardiac; Female; Humans; Male; Middle | 1993 |
Amiodarone and post-MI patients.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Death, Sudden, Cardiac; | 1993 |
[Ventricular arrhythmias after myocardial infarction: risk classification and treatment concepts].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia A | 1995 |
Use of amiodarone in the postmyocardial infarction patient.
Topics: Amiodarone; Cause of Death; Clinical Trials as Topic; Electrocardiography; Humans; Myocardial Infarc | 1995 |
[Secondary prevention after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Aspirin; Calcium Channel Blockers; | 1993 |
Pharmacological therapy in coronary heart disease: prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death.
Topics: Action Potentials; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Cal | 1993 |
Secondary prevention after myocardial infarction with class III antiarrhythmic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sudden, C | 1993 |
Amiodarone-induced epididymitis: report of a new case and literature review of 12 cases.
Topics: Amiodarone; Anti-Bacterial Agents; Cohort Studies; Epididymitis; Humans; Male; Mass Screening; Middl | 1993 |
Should post-infarction asymptomatic ventricular arrhythmias be treated? The need for caution.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Heart Ventricles; | 1995 |
What have clinical trials taught us about proarrhythmia?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiogra | 1996 |
Assessment of arrhythmias after myocardial infarction in the post-CAST era.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiogra | 1996 |
Evaluation and treatment of nonsustained ventricular tachycardia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomegaly; Cardiomyopathy, Dilated; Electrocardiography; Hear | 1996 |
[Stratification of arrhythmia risk and therapeutic options in survivors of acute myocardial infarction].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Tria | 1996 |
Major clinical trials assessing the prophylactic use of amiodarone in patients with ventricular tachyarrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Myo | 1996 |
[Anti-arrhythmia therapy after myocardial infarct: preliminary results of EMIAT and CAMIAT studies].
Topics: Adult; Aged; Amiodarone; Death, Sudden, Cardiac; Electrocardiography, Ambulatory; Female; Heart Cond | 1996 |
[Ventricular cardiac arrhythmias. New anti-arrhythmia agents].
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Electrocardiography; Heart Conduction | 1996 |
Amiodarone: a late comer.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Failure; Heart Ventricles; Humans; M | 1997 |
Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Chronic Disease; Cont | 1997 |
What can we expect from prophylactic implantable defibrillators?
Topics: Amiodarone; Anti-Arrhythmia Agents; Cause of Death; Death, Sudden, Cardiac; Defibrillators, Implanta | 1997 |
Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduction System; Humans; Myocardia | 1997 |
Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Female; Hear | 1997 |
Antiarrhythmic therapy in the post-infarction setting: update from major amiodarone studies.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Male; Middle Aged; Myocard | 1998 |
Amiodarone and "primary" prevention of sudden death: critical review of a decade of clinical trials.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden, Cardiac; Female; | 1999 |
Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Humans; M | 1999 |
Arrhythmic risk stratification of post-myocardial infarction patients.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Electrophysiology; | 2000 |
Amiodarone: clinical trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sudden; D | 2000 |
Amiodarone: what have we learned from clinical trials?
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden, Cardiac; Defibrillators | 2000 |
Beta-blockers and amiodarone for the primary prevention of sudden cardiac death.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Heart Failu | 1999 |
The role of antiarrhythmic therapy in the management of nonsustained ventricular tachycardia.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Electr | 1999 |
[Hyperthyroidism and heart].
Topics: Amiodarone; Angina Pectoris; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Dilated; D | 2001 |
Amiodarone -- waxed and waned and waxed again.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Pres | 2001 |
[Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; A | 2001 |
Prevention of sudden coronary death by chronic antiarrhythmic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Bretylium Compounds; Clinical Trials as Topic; Death, | 1978 |
[Mishaps with anti-arrhythmic agents used to reduce mortality after infarction].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Myocardial Infarction | 1992 |
[Ventricular tachycardia in anterior wall aneurysm after myocardial infarct].
Topics: Aged; Amiodarone; Drug Therapy, Combination; Electrocardiography, Ambulatory; Heart Aneurysm; Heart | 1992 |
Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiac C | 1990 |
Rationale of combination antiarrhythmic drug therapy.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Bretylium Compounds; Digitalis Glyc | 1985 |
56 trials available for amiodarone and Myocardial Infarction
| Article | Year |
|---|---|
Ventricular tachycardia characteristics and outcomes with catheter ablation vs. antiarrhythmic therapy: insights from the VANISH trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Humans; Myocardial Infarction; Tachycardia, V | 2022 |
Ventricular Tachycardia and ICD Therapy Burden With Catheter Ablation Versus Escalated Antiarrhythmic Drug Therapy.
Topics: Adenosine Triphosphate; Aged; Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Defibrillators, | 2023 |
Clinical and Electrocardiographic Characteristics of Electrical Storms Due to Monomorphic Ventricular Tachycardia Refractory to Intravenous Amiodarone.
Topics: Aged; Aged, 80 and over; Amiodarone; Drug Resistance; Electrocardiography; Female; Humans; Male; Mid | 2015 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Defibrillators, Impla | 2016 |
Prognostic factors affecting the all-cause death and sudden cardiac death rates of post myocardial infarction patients with low left ventricular ejection fraction.
Topics: Aged; Amiodarone; Angioplasty, Balloon; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Ag | 2009 |
Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Hospit | 2002 |
Long-term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT).
Topics: Administration, Oral; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Cardiac | 2003 |
Lower observed versus expected (based on U.S. age and gender specific rates) survival in patients treated for near-fatal ventricular arrhythmias.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Output; Case-Control Studies; Cohort Studies; Conf | 2004 |
Response to programmed ventricular stimulation and clinical outcome in cardiac arrest survivors receiving randomised assignment to implantable cardioverter defibrillator or antiarrhythmic drug therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Electrophysiologic Techniques, Card | 2004 |
Characterization of QT interval adaptation to RR interval changes and its use as a risk-stratifier of arrhythmic mortality in amiodarone-treated survivors of acute myocardial infarction.
Topics: Adaptation, Physiological; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Causality; Comorbidity; D | 2004 |
Individual patterns of dynamic QT/RR relationship in survivors of acute myocardial infarction and their relationship to antiarrhythmic efficacy of amiodarone.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiograp | 2004 |
[Dynamics of postinfarction left ventricular remodeling during long term use of perindopril, amiodarone, and beta-adrenoblockers].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Drug | 2005 |
HRV scaling exponent identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone.
Topics: Adolescent; Adult; Aged; Algorithms; Amiodarone; Diagnosis, Computer-Assisted; Electrocardiography; | 2006 |
Decreased mortality in a rat model of acute postinfarction heart failure.
Topics: Amiodarone; Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Critical Care; Diseas | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Cicatrix; Cohort Studies; Combined Modality Th | 2006 |
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2006 |
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
Topics: Aged; Amiodarone; Captopril; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; | 2008 |
Procainamide, oxprenolol and amiodarone as antidysrhythmic drugs in myocardial infarction.
Topics: Amiodarone; Benzofurans; Cardiac Complexes, Premature; Clinical Trials as Topic; Death, Sudden; Doub | 1980 |
The value of amiodarone for the treatment of unstable angina.
Topics: Adult; Aged; Amiodarone; Angina Pectoris; Angina, Unstable; Benzofurans; Drug Evaluation; Drug Thera | 1983 |
[Use of cordarone in acute myocardial infarct].
Topics: Amiodarone; Anti-Arrhythmia Agents; Benzofurans; Clinical Trials as Topic; Humans; Middle Aged; Myoc | 1982 |
[Experience with the clinical study of cordaron].
Topics: Adult; Aged; Amiodarone; Angina Pectoris; Anti-Arrhythmia Agents; Benzofurans; Clinical Trials as To | 1980 |
Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death.
Topics: Aged; Amiodarone; Cardiac Complexes, Premature; Death, Sudden, Cardiac; Female; Humans; Male; Metopr | 1993 |
Does amiodarone reduce sudden death and cardiac mortality after myocardial infarction? The European Myocardial Infarct Amiodarone Trial (EMIAT).
Topics: Adult; Aged; Amiodarone; Death, Sudden, Cardiac; Europe; Female; Humans; Male; Middle Aged; Myocardi | 1994 |
Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): rationale and protocol. CAMIAT Investigators.
Topics: Amiodarone; Canada; Humans; Myocardial Infarction; Pilot Projects; Proportional Hazards Models; Rese | 1993 |
The European Myocardial Infarct Amiodarone Trial (EMIAT). EMIAT Investigators.
Topics: Amiodarone; Arrhythmias, Cardiac; Europe; Female; Humans; Male; Middle Aged; Myocardial Infarction; | 1993 |
Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction.
Topics: Amiodarone; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Follow-Up Studies; Heart Ventricles; Human | 1993 |
[Long-term effect of amiodarone therapy following myocardial infarct in patients with complex ventricular arrhythmias].
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Female; Heart Ventricles; Humans; Ma | 1993 |
[The influence of amiodarone on results of the signal-averaged electrocardiogram].
Topics: Adult; Aged; Amiodarone; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarcti | 1996 |
Lack of effect of amiodarone on survival after extensive infarction. Polish Amiodarone Trial.
Topics: Amiodarone; Echocardiography; Humans; Middle Aged; Myocardial Infarction; Retrospective Studies; Str | 1996 |
[Prediction of long-term efficacy of amiodarone for refractory ventricular tachycardia: clinical significance of electrophysiologic study and Holter monitoring].
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Deat | 1996 |
Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Double-Blind | 1997 |
Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Double-Blind | 1997 |
Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Double-Blind | 1997 |
Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Double-Blind | 1997 |
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sud | 1997 |
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sud | 1997 |
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sud | 1997 |
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sud | 1997 |
Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Drug Interactions; Dru | 1999 |
Relation of mean heart rate and heart rate variability in patients with left ventricular dysfunction.
Topics: Adult; Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Electrocardiography, Ambulato | 1999 |
Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA study investigators, GEMA Group, Buenos Aires, Argentina. Grupo de Estudios Multicéntricos en Argentina.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; H | 2000 |
Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cause of Death; Electrocardiography, | 2000 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2002 |
Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Disease-Fre | 2002 |
Prevention of sudden coronary death by chronic antiarrhythmic therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Bretylium Compounds; Clinical Trials as Topic; Death, | 1978 |
Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study.
Topics: Amiodarone; Chi-Square Distribution; Double-Blind Method; Drug Tolerance; Feasibility Studies; Follo | 1992 |
Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Female; Humans; Male; Middle Aged; Myocardial Infarction; St | 1992 |
Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiac C | 1990 |
[Amiodarone and secondary prevention. The EMIAT study].
Topics: Amiodarone; Cardiac Complexes, Premature; Death, Sudden, Cardiac; Double-Blind Method; Humans; Myoca | 1991 |
Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study.
Topics: Amiodarone; Dose-Response Relationship, Drug; Electrophysiology; Humans; Myocardial Infarction; Pati | 1991 |
Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS)
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden; Female; Humans; Male; Middl | 1990 |
Antiarrhythmic treatment and myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Myocardial Infarction; Research De | 1990 |
[Anti-arrhythmic effect of cordaron in patients with unstable stenocardia and myocardial infarction].
Topics: Adult; Aged; Amiodarone; Angina Pectoris; Angina, Unstable; Cardiac Complexes, Premature; Clinical T | 1989 |
Intravenous amiodarone in acute anterior myocardial infarction: a controlled study.
Topics: Acute Disease; Adult; Aged; Amiodarone; Female; Humans; Injections, Intravenous; Male; Middle Aged; | 1989 |
[Comparative efficacy of amiodarone and propranolol on ventricular arrhythmia in the post-infarction period].
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Electrocardiography; Female; Follow-Up Studies; Humans; Male | 1989 |
Comparison of the efficacy of propranolol and amiodarone in suppressing ventricular arrhythmias following myocardial infarction.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Female; Follow-Up Studies; Heart Ventricles; Humans; Male; M | 1989 |
Antithyroid antibodies as an early marker for thyroid disease induced by amiodarone.
Topics: Adult; Aged; Amiodarone; Antibody Formation; Autoantibodies; Autoimmune Diseases; Benzofurans; Doubl | 1986 |
Amiodarone in the management of atrial fibrillation complicating myocardial infarction.
Topics: Amiodarone; Atrial Fibrillation; Benzofurans; Digoxin; Humans; Myocardial Infarction | 1986 |
[Amiodarone in acute myocardial infarction: a preliminary clinical trial].
Topics: Adult; Amiodarone; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial Infarctio | 1987 |
Effectiveness of amiodarone on ventricular arrhythmias during and after acute myocardial infarction.
Topics: Amiodarone; Arrhythmias, Cardiac; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Moni | 1987 |
[Intravenous administration of lidocaine and amiodarone in patients with acute myocardial infarction].
Topics: Amiodarone; Arrhythmias, Cardiac; Benzofurans; Female; Humans; Injections, Intravenous; Lidocaine; M | 1985 |
167 other studies available for amiodarone and Myocardial Infarction
| Article | Year |
|---|---|
Development of Robust 17(
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Arachidonic Acids; Dose-Response Relationship | 2019 |
Pharmacologic therapy for engraftment arrhythmia induced by transplantation of human cardiomyocytes.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cell Line; Cell- and Tissue-Based | 2021 |
Effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI).
Topics: Amiodarone; Atorvastatin; Cardiovascular Agents; Case-Control Studies; China; Creatine Kinase, MB Fo | 2021 |
Use of an antiarrhythmic drug against acute selenium toxicity.
Topics: Acute Disease; Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Blood Vessels; Myo | 2020 |
Amiodarone Treatment in the Early Phase of Acute Myocardial Infarction Protects Against Ventricular Fibrillation in a Porcine Model.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Female; Hear | 2019 |
Quinidine-Responsive Polymorphic Ventricular Tachycardia in Patients With Coronary Heart Disease.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Coronary Artery Disease; Drug Evaluation; Drug Resistance; | 2019 |
Inhibition of thyroid hormone receptor α1 impairs post-ischemic cardiac performance after myocardial infarction in mice.
Topics: Amiodarone; Animals; Calcium-Binding Proteins; Dronedarone; Hypertrophy, Left Ventricular; Male; Mic | 2013 |
Prophylactic amiodarone and lidocaine improve survival in an ovine model of large size myocardial infarction.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Disease Mode | 2013 |
Benefits of standardizing the treatment of arrhythmias in the sheep (Ovis aries) model of chronic heart failure after myocardial infarction.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Catheters; Disease Models, Animal | 2013 |
Antiarrhythmic efficacy of CPUY102122, a multiple ion channel blocker, on rabbits with ischemia/reperfusion injury.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Antioxidants; Cardiotonic Agents; CHO Cells; Connexin 4 | 2014 |
Dronedarone does not affect infarct volume as assessed by magnetic resonance imaging in a porcine model of myocardial infarction.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Biomarkers; Coronary Vessels; Disease Models, Animal; D | 2015 |
Clinical criteria for predicting benefit of ICD/PM in post myocardial infarction patients: an AVID and CAST analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sudden, C | 2008 |
Free radical lipid peroxidation during amiodarone therapy for postinfarction cardiosclerosis.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Antioxidants; Free Radicals; Lipid Peroxidation; Myocar | 2008 |
Preventive effect of amiodarone during acute period in isoproterenol-induced myocardial injury in Wistar rats.
Topics: Amiodarone; Animals; Cardiotonic Agents; Disease Models, Animal; Isoproterenol; Male; Myocardial Inf | 2009 |
[Difficult-to-treat atrial fibrillation in a patient on haemodialysis].
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Atrial Fibrillation; Bisoprolol; Bradycardia; Calcium | 2010 |
[Acute myocardial infarction following persistent atrial fibrillation. Consequence, common etiology or a case?].
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Coron | 2010 |
Skeletal myoblast implants induce minor propagation delays, but do not promote arrhythmias in the normal swine heart.
Topics: Action Potentials; Amiodarone; Animals; Female; Heart Ventricles; Myoblasts, Skeletal; Myocardial In | 2010 |
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cohort Studies; Confidence Intervals; Dose-Response Relati | 2011 |
Drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction: What does the crystal ball tell you?
Topics: Amiodarone; Anti-Arrhythmia Agents; Critical Care; Critical Illness; Electrocardiography; Female; Hu | 2011 |
[Effects of combined amiodarone and antiarrhythmic peptide use on the cardiac gap junctions and incidence of induced ventricular arrhythmias in healed myocardial infarction rabbit models].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Connexin 43; Male; Myocardial Inf | 2010 |
Letter by Ayalloore and LeLorier regarding article, "Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency with Ranolazine for Less Isc
Topics: Acetanilides; Acute Coronary Syndrome; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; E | 2011 |
Reduction of myocardial infarct size by dronedarone in pigs--a pleiotropic action?
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Blood Pressure; Calcium; Cardiotonic Agents; Coronary C | 2011 |
The effects of allitridi and amiodarone on the conduction system and reverse use-dependence in the isolated hearts of rats with myocardial infarction.
Topics: Action Potentials; Allyl Compounds; Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardia | 2012 |
Implantable cardiac defibrillators.
Topics: Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibrillators, Implantable; Humans; | 2002 |
Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Death, Sudden, | 2002 |
Life support treatment.
Topics: Adenosine; Amiodarone; Anti-Arrhythmia Agents; Electric Countershock; Humans; Life Support Care; Myo | 2002 |
Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Myocardial Infa | 2002 |
Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiac Pacing, Artifici | 2003 |
Clusters of ventricular fibrillation in a patient with an implantable cardioverter difibrillator treated with amiodarone.
Topics: Adult; Amiodarone; Angioplasty, Balloon, Coronary; Defibrillators, Implantable; Electrocardiography; | 2003 |
Successful resuscitation of a patient with electrical storm.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Electric Countershock; Female; | 2003 |
Effect of amiodarone on the descending limb of the T wave.
Topics: Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Electrocard | 2003 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
Can we predict antiarrhythmic efficacy or inefficacy of amiodarone or any other antiarrhythmic? What this patient needs is a doctor!
Topics: Amiodarone; Anti-Asthmatic Agents; Electrocardiography; Forecasting; Humans; Myocardial Infarction | 2004 |
Effect of amiodarone dose on the risk of permanent pacemaker insertion.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cohort Stud | 2004 |
Effects of high- and low-dose amiodarone on mortality, left ventricular remodeling, and hemodynamics in rats with experimental myocardial infarction.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Body Weight; Dose-Response Relationship, Drug; Female; | 2004 |
Usefulness of ventricular repolarization dynamicity in predicting arrhythmic deaths in patients with ischemic cardiomyopathy (from the European Myocardial Infarct Amiodarone Trial).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Death; Electrocard | 2005 |
The influence of extracellular acidosis on the effect of IKr blockers.
Topics: Acidosis; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Dose-Response Relationship | 2005 |
Summaries for patients. Potential benefits of amiodarone for patients undergoing open-heart surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardi | 2005 |
Fatal case of amiodarone-induced acute respiratory distress syndrome in a patient with severe left ventricular dysfunction due to extensive anterior acute myocardial infarction.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Fatal Outcome; Humans; Male; Myocardial Infarction; Respir | 2006 |
Management of cardiovascular risk in patients receiving calcineurin inhibitors--a case report.
Topics: Acenocoumarol; Amiodarone; Angioplasty; Calcineurin Inhibitors; Carbazoles; Carvedilol; Cyclosporine | 2006 |
[Eleven-years long follow-up in a patient after myocardial infarction, with low ejection fraction and recurrent ventricular tachycardia. The role of implantable cardioverter defibrillator and selective ablation].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Defibrillators, Implantable; Electrophy | 2006 |
A novel SOD-mimetic permeability transition inhibitor agent protects ischemic heart by inhibiting both apoptotic and necrotic cell death.
Topics: Amiodarone; Animals; Apoptosis; Cytochromes c; Humans; Ischemia; Jurkat Cells; Magnetic Resonance Sp | 2006 |
Regression of bilateral optic disc edema after discontinuation of amiodarone.
Topics: Amiodarone; Female; Follow-Up Studies; Humans; Middle Aged; Myocardial Infarction; Papilledema; Subs | 2006 |
Amiodarone induced skin necrosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Eruptions; Humans; Male; Middle Aged; | 2006 |
[Polymorphic ventricular tachycardia in acute myocardial infarction without ST elevation in a patient with thrombocytopenia].
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Coronary Angiography; Electrocardiography; | 2006 |
Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study.
Topics: Aged; Amiodarone; Anesthesia, Local; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autonomic Nerve B | 2007 |
Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dronedarone; | 2007 |
Multiple tachycardia forms occurring in a patient with Wolff-Parkinson-White syndrome and acute myocardial infarction.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiotonic Agents; Dopamine; Drug Therapy, | 2007 |
Conduction disturbances and paroxysmal atrial fibrillation during acute inferior myocardial infarction.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Atrial | 2008 |
Comparative effects of acute vs. chronic oral amiodarone treatment during acute myocardial infarction in rats.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Catech | 2007 |
[Bi-tachycardia and ischemic cardiopathy (following myocardial infarction)].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Echocardiography; Electrophysiology; Female; Humans | 2007 |
Prognostic significance of electrocardiographic findings in angina at rest. Therapeutic implications.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angina Pectoris; Coronary Angiography; Electro | 1981 |
Ventricular ectopy: etiology, evaluation, and therapy.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angina Pectoris; Anti-Arrhythmia Agents; Aprindine; Arrhyth | 1982 |
Wide QRS tachycardia: multiple mechanisms in a patient after myocardial infarction.
Topics: Adult; Amiodarone; Cardiac Pacing, Artificial; Drug Therapy, Combination; Electrocardiography; Heart | 1984 |
Rapid ventricular tachycardia due to His-Purkinje reentry.
Topics: Adult; Aged; Amiodarone; Bundle of His; Cardiac Pacing, Artificial; Electrocardiography; Heart Condu | 1984 |
Interaction of amiodarone and diphenylhydantoin.
Topics: Aged; Amiodarone; Ataxia; Benzofurans; Drug Interactions; Humans; Male; Myocardial Infarction; Pheny | 1984 |
Slate-gray pigmentation of sun-exposed skin induced by amiodarone.
Topics: Amiodarone; Benzofurans; Humans; Male; Middle Aged; Myocardial Infarction; Photosensitivity Disorder | 1984 |
[Morphological criteria of the effectiveness of using kordaron and obzidan in experimental myocardial ischemia].
Topics: Amiodarone; Animals; Benzofurans; Coronary Disease; Dogs; Drug Evaluation, Preclinical; Histocytoche | 1984 |
Hemodynamic effects of antiarrhythmic drugs in acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Cardiac Output; Central Ve | 1984 |
Ventricular fibrillation in a conscious canine preparation of sudden coronary death--prevention by short- and long-term amiodarone administration.
Topics: Amiodarone; Animals; Benzofurans; Consciousness; Coronary Disease; Death, Sudden; Dogs; Electrocardi | 1983 |
[Interstitial and alveolar lung changes following treatment with amiodarone].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Benzofurans; Female; Humans; Myocardial Infarction; Pulmon | 1983 |
[Incidence of undesirable effects in long-term treatment with amiodarone].
Topics: Adolescent; Adult; Aged; Amiodarone; Benzofurans; Eye; Female; Heart Rate; Humans; Hyperthyroidism; | 1983 |
[Drug therapy of atrial fibrillation in acute myocardial infarct: comparison of intravenous amiodarone and digoxin].
Topics: Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Digoxin; Female; Humans; Injections, Intravenous | 1983 |
[Amiodarone, a new anti-arrhythmia agent in arrhythmia associated with myocardial infarct].
Topics: Amiodarone; Arrhythmias, Cardiac; Benzofurans; Female; Humans; Middle Aged; Myocardial Infarction | 1983 |
Replacement of amiodarone by sotalol for repetitive ventricular premature beats.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Female; Humans; Male; Middle Aged; Myocardial I | 1984 |
Prognosis after sudden cardiac death without associated myocardial infarction: one year follow-up of empiric therapy with amiodarone.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Death, Sudden; Dose-Response Relationshi | 1984 |
[Effect of cordarone on the ultrastructure of cardiac muscle cells in experimental myocardial infarct].
Topics: Amiodarone; Animals; Benzofurans; Cats; Drug Evaluation, Preclinical; Heart; Microscopy, Electron; M | 1984 |
[Effect of previous administration of amiodarone on the early incidence of ventricular fibrillation during experimental myocardial ischemia].
Topics: Amiodarone; Animals; Benzofurans; Blood Pressure; Disease Models, Animal; Heart Rate; Male; Myocardi | 1984 |
[Effect of amiodarone treatment on the myocardial infart size in experimental dogs].
Topics: Amiodarone; Animals; Benzofurans; Dogs; Electrocardiography; Female; Male; Myocardial Infarction; Pr | 1984 |
Dangers of amiodarone and anticoagulant treatment.
Topics: Aged; Amiodarone; Benzofurans; Drug Interactions; Humans; Male; Myocardial Infarction; Prothrombin T | 1981 |
Intravenous amiodarone in atrial fibrillation complicating myocardial infarction.
Topics: Aged; Amiodarone; Atrial Fibrillation; Benzofurans; Humans; Infusions, Parenteral; Male; Middle Aged | 1982 |
Intravenous amiodarone in atrial fibrillation complicating myocardial infarction.
Topics: Amiodarone; Atrial Fibrillation; Benzofurans; Humans; Myocardial Infarction; Time Factors | 1982 |
Intravenous amiodarone in atrial fibrillation complicating myocardial infarction.
Topics: Amiodarone; Atrial Fibrillation; Benzofurans; Humans; Injections, Intravenous; Myocardial Infarction | 1982 |
[Effect of cordarone (amiodarone) on the circulatory system of patients with recent myocardial infarction].
Topics: Aged; Amiodarone; Benzofurans; Hemodynamics; Humans; Male; Middle Aged; Myocardial Infarction | 1983 |
Studies of amiodarone during experimental myocardial infarction: beneficial effects on hemodynamics and infarct size.
Topics: Amiodarone; Animals; Autoradiography; Benzofurans; Coronary Circulation; Coronary Vessels; Dogs; Hem | 1982 |
Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Coronary Disease; Female; Heart Failure; | 1982 |
Electrophysiologic observations of concealed ventricular depolarizations due to amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Benzofurans; Electrophysiology; Exercise Test; Humans; Male; Mid | 1982 |
[Effect of cordaron on the threshold of ventricular fibrillation in cats].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Benzofurans; Cats; Female; Male; Myocardial Contraction | 1982 |
[Prajmalium bitartrate in hyperkinetic ventricular arrhythmias in infarct patients during rehabilitation].
Topics: Adult; Aged; Ajmaline; Ambulatory Care; Amiodarone; Arrhythmias, Cardiac; Drug Therapy, Combination; | 1981 |
Amiodarone and the heart.
Topics: Amiodarone; Atrial Fibrillation; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Heart Fai | 1995 |
Amiodarone for patients with ventricular premature depolarizations after myocardial infarction. Is it safe to stop treatment at one year?
Topics: Amiodarone; Cardiac Complexes, Premature; Humans; Myocardial Infarction; Time Factors | 1993 |
Antiarrhythmic drug prescription in patients after myocardial infarction in the last decade. Experience of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Female; Humans; Italy; Male; Myo | 1995 |
Safety of thrombolytic treatment in patients with central venous cannulation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Catheterization, Central Venous; Contraindications; Fema | 1995 |
Sudden cardiac death and the potential role of beta adrenoceptor-blocking drugs.
Topics: Adrenergic beta-Antagonists; Amiodarone; Death, Sudden, Cardiac; Humans; Myocardial Infarction | 1994 |
Sixty-six episodes of ventricular fibrillation within four hours: electrical stability restored by propafenone.
Topics: Amiodarone; Electric Countershock; Humans; Injections, Intravenous; Lidocaine; Male; Middle Aged; My | 1994 |
Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Analysis of Variance; Angiocardiography; Electrophysiolo | 1993 |
Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experimental study.
Topics: Amiodarone; Animals; Disease Models, Animal; Dogs; Electric Stimulation; Epinephrine; Female; Heart | 1994 |
[Pulmonary toxicity due to amiodarone].
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Humans; Lung; Male; Middle Aged; Myocardial Infarction; Myoc | 1993 |
[Dispersion of ventricular recovery time as a new marker of arrhythmogenic risk].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Dise | 1995 |
Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Deat | 1996 |
Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists?
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Defibrillators, Im | 1996 |
The SWORD of Damocles.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Myocardial Infarction; Randomized | 1996 |
Ultrastructural evidence of thyroid damage in amiodarone-induced thyrotoxicosis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Biopsy, Needle; Humans; Male; Microscopy, Electron; Myocar | 1995 |
The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrophysiolog | 1996 |
From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduct | 1996 |
[Amiodarone in arrhythmia].
Topics: Amiodarone; Arrhythmias, Cardiac; Humans; Myocardial Infarction | 1996 |
[Implantable automatic defibrillator after MADIT and EMIAT].
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Death, Sudden; Defibrillators, Implant | 1996 |
Amiodarone after myocardial infarction: EMIAT and CAMIAT trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Myocardial Infarction; Ventricular Dysfunction, Left | 1997 |
Amiodarone after myocardial infarction: EMIAT and CAMIAT trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Myocardi | 1997 |
Amiodarone after myocardial infarction: EMIAT and CAMIAT trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Humans; Myocardial Infarction; Ventric | 1997 |
[Etiologies of electric storm].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Bretylium Tosylate; Electric Countershock; Female; Hemodyn | 1997 |
[Comparative evaluation of the effect of dimebon, obzidan, finoptin, and cordarone on the functional state of the ischemic focus and the size of necrosis zone during experimental myocardial infarction].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cats; Histamine H1 Antagonists; Indoles; Myocardial Inf | 1996 |
[Arrhythmia as risk factor].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Myocardial Infarction; Risk Factor | 1997 |
[Amiodaron improves prognosis in high risk patients].
Topics: Aged; Amiodarone; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Risk Fact | 1997 |
[Amiodarone in heart failure. Information from GESICA (Study Group on Survival of Heart Failure in Argentina) and CHFSTAT (Veterans Affairs Cooperative Study Program)].
Topics: Amiodarone; Anti-Arrhythmia Agents; Heart Failure; Heart Rate; Humans; Myocardial Infarction | 1996 |
The amiodarone trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Myocardi | 1997 |
[Death is still a death. Does it matter if the cause is myocardial infarction or arrhythmia?].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cause of Death; Follow-Up Studies; Humans; | 1998 |
Effect of amiodarone on mortality.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Humans; Myo | 1998 |
Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial).
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Tria | 1998 |
Amiodarone and mortality in CHF and post-MI.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden; Heart Failure; Human | 1998 |
Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cost-Benefit Analysis; Decision Support Te | 1998 |
Cost-effectiveness of tests to assess the risk of sudden death after acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cost-Benefit Analysis; Death, Sudden; Deci | 1998 |
[Amiodarone and thyroid function: clinical implications].
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Hyperthyroidism; Male; Myocardial Infarction; Ta | 1998 |
Spontaneous termination of ventricular tachycardia with variable patterns and variable mechanisms?
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Electrop | 1999 |
Hyperkalemia probably reverses the antiarrhythmic effects of amiodarone: a case report.
Topics: Acute Kidney Injury; Amiodarone; Anti-Arrhythmia Agents; Humans; Hyperkalemia; Male; Middle Aged; My | 1999 |
Heart failure: a diagnostic and therapeutic dilemma in elderly patients.
Topics: Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as Topic; Death | 1999 |
[Role of electrophysiology in the prognosis and therapy of cardiomyopathies].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopath | 1999 |
Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats.
Topics: Action Potentials; Age Factors; Amiodarone; Animals; Arrhythmias, Cardiac; Dose-Response Relationshi | 2000 |
Amiodarone after acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Humans; Myocardial Infarction | 2000 |
Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.
Topics: Adrenergic Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Dogs; Dronedarone; Echocardiogr | 2000 |
[Diagnostic quiz. Increasing dyspnea after bypass operation. Interstitial lung disease].
Topics: Aged; Amiodarone; Coronary Artery Bypass; Humans; Lung Diseases, Interstitial; Male; Myocardial Infa | 2001 |
Intravenous amiodarone decreases the duration of atrial fibrillation associated with acute myocardial infarction.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Female; Hemodynamics; Humans | 2001 |
Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cost-Benef | 2001 |
Summaries for patients. Cost-effectiveness of implantable defibrillators versus the drug amiodarone to prevent abnormal heart rhythms after heart attack.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Computer S | 2001 |
Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia; long-term outcome in relation to acute electrophysiological findings.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Defibrillators, | 2002 |
Assessment and monitoring in clinical trials when survival curves have distinct shapes: a Bayesian approach with Weibull modelling.
Topics: Amiodarone; Anti-Arrhythmia Agents; Bayes Theorem; Clinical Trials as Topic; Computer Simulation; Hu | 2002 |
[Drug therapy of tachyarrhythmias (author's transl)].
Topics: Action Potentials; Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Aprind | 1978 |
[Continuous ambulatory electrocardiographic recordings using the Holter system in the late phase of hospitalization for recent myocardial infarct. Value and limitations studied in a series of 100 patients].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Ambulatory Care; Amiodarone; Arrhythmias, Cardiac; Coronar | 1979 |
Amiodarone in the treatment of refractory supraventricular and ventricular arrhythmias.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Corneal Diseases; Drug Administration Sc | 1979 |
Effect of cordaron on the ischaemic myocardium and its blood vessels. An experimental study.
Topics: Amiodarone; Animals; Benzofurans; Blood Vessels; Connective Tissue; Coronary Circulation; Coronary D | 1979 |
[Skin pigmentation caused by amiodarone].
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Cornea; Female; Humans; Male; Middle Age | 1978 |
[Treatment of atrial flutter and fibrillation with amiodarone and digitalis].
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Digoxin; Female; Humans; | 1977 |
Electrophysiologic and pharmacologic studies in a patient with acute myocardial infarction complicated by intraventricular and atrioventricular block.
Topics: Amiodarone; Bundle-Branch Block; Electrocardiography; Electrophysiology; Heart Block; Heart Conducti | 1975 |
The amiodarone odyssey.
Topics: Amiodarone; Drug Evaluation; Humans; Myocardial Infarction | 1992 |
Stabilization of cardiac rhythm in subsequently fatal ventricular tachycardia and fibrillation by calcitonin gene-related peptide.
Topics: Amiodarone; Calcitonin Gene-Related Peptide; Electric Countershock; Electrocardiography, Ambulatory; | 1992 |
Antiadrenergic cardiovascular adverse effects of high-dose amiodarone loading regimen.
Topics: Administration, Oral; Amiodarone; Cardiac Output, Low; Catecholamines; Humans; Male; Middle Aged; My | 1992 |
Antiarrhythmic effect of chronic oral amiodarone treatment in dogs with myocardial infarction and reproducibly inducible sustained ventricular arrhythmias.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Elect | 1990 |
Effects of amiodarone on cardiac electrophysiology and inducibility of arrhythmias in chronically infarcted dogs: late arrhythmias, haemodynamics, and sympatholytic actions.
Topics: Action Potentials; Amiodarone; Animals; Arrhythmias, Cardiac; Chronic Disease; Dogs; Electrocardiogr | 1990 |
Effects of amiodarone on myocardial performance in normal canine hearts and canine hearts with infarcts.
Topics: Amiodarone; Animals; Blood Pressure; Dog Diseases; Dogs; Heart; Heart Rate; Hemodynamics; Myocardial | 1991 |
Relationship between myocardial amiodarone concentration and antiarrhythmic effect in dogs with myocardial infarction and electrically induced ventricular arrhythmias.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Heart | 1991 |
Polymorphous ventricular tachycardia associated with acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Coronary Angiography; Electrocardiograp | 1991 |
Aspergillus myocarditis presenting as myocardial infarction with complete heart block.
Topics: Aged; Amiodarone; Aspergillosis; Aspergillus flavus; Heart; Heart Block; Humans; Lung Diseases; Male | 1990 |
Long-term follow-up of postmyocardial infarction patients with ventricular tachycardia or ventricular fibrillation treated with amiodarone.
Topics: Aged; Amiodarone; Cardiac Pacing, Artificial; Female; Follow-Up Studies; Heart; Humans; Life Tables; | 1990 |
Antiarrhythmic drugs. Clinical pharmacology of the old and the new agents.
Topics: Acecainide; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden; Delayed-Action | 1985 |
[Anti-arrhythmic action of combinations of trimecaine with quinidine, novocainamide and cordaron (clinico-experimental study)].
Topics: Acetanilides; Amiodarone; Animals; Arrhythmias, Cardiac; Benzofurans; Cardiac Complexes, Premature; | 1985 |
The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction.
Topics: Amiodarone; Animals; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Dogs; Dose-Response Relatio | 1988 |
[Non-arteriosclerotic myocardial infarction in a 24-year-old patient and unintended use of amiodarone during pregnancy without embryotoxic effects].
Topics: Abnormalities, Drug-Induced; Adult; Amiodarone; Cardiac Complexes, Premature; Coronary Aneurysm; Emb | 1988 |
Antiarrhythmic effects of desethylamiodarone in dogs with subacute myocardial infarction and inducible ventricular arrhythmias.
Topics: Amiodarone; Animals; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Infusions, Intravenous; Male; | 1989 |
Acute electrophysiologic effects and antiarrhythmic/antifibrillatory activity of intravenous amiodarone in a chronic feline infarction model.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cats; Chronic Disease; Electric Stimulation; Electrophy | 1989 |
Differential electrophysiological effects of amiodarone on ventricular muscle and Purkinje fibers in canine one-day-old myocardial infarction.
Topics: Action Potentials; Amiodarone; Animals; Coronary Disease; Dogs; Electric Stimulation; Electrophysiol | 1989 |
[Multicenter clinical trial on the prevention of sudden death after myocardial infarction by the use of anti-arrhythmia agents. Investigator Group of the Spanish Study on Sudden Death].
Topics: Amiodarone; Arrhythmias, Cardiac; Captopril; Death, Sudden; Humans; Metoprolol; Multicenter Studies | 1989 |
[Loading tests in assessing the treatment of patients having had a myocardial infarct].
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Angina Pectoris; Coronary Circulation; Delayed-Actio | 1988 |
A practical regimen for intravenous amiodarone.
Topics: Adult; Aged; Amiodarone; Benzofurans; Humans; Infusions, Parenteral; Middle Aged; Myocardial Infarct | 1986 |
The effect of intravenous amiodarone on heart rate in patients with acute myocardial infarction or ischemia and sinus tachycardia.
Topics: Aged; Aged, 80 and over; Amiodarone; Coronary Disease; Female; Heart Rate; Humans; Infusions, Intrav | 1988 |
[Hyperkinetic ventricular arrhythmias in acute myocardial infarction: different etiopathogenetic mechanisms?].
Topics: Aged; Amiodarone; Electric Countershock; Electrocardiography; Female; Humans; Lidocaine; Male; Middl | 1987 |
[Effect of cordarone on the size of the lesion in patients with acute myocardial infarction].
Topics: Acute Disease; Adult; Aged; Amiodarone; Blood Pressure; Creatine Kinase; Electrocardiography; Humans | 1987 |
Granular cells as a marker of early amiodarone hepatotoxicity: a pathological and analytical study.
Topics: Amiodarone; Chemical and Drug Induced Liver Injury; Cytoplasmic Granules; Female; Humans; Iodine; Li | 1987 |
Electrophysiologic predictors of long-term clinical outcome with amiodarone for refractory ventricular tachycardia secondary to coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Cardiac Pacing, Artificial; Female; Follow-Up Studies; H | 1987 |
Distribution of amiodarone and desethylamiodarone in a patient with acute myocardial infarction after intravenous administration.
Topics: Amiodarone; Female; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Tissu | 1987 |
Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval.
Topics: Adolescent; Adult; Aged; Amiodarone; Electrocardiography; Female; Follow-Up Studies; Humans; Male; M | 1986 |
[Intravenous amiodarone in life-threatening ventricular arrhythmias].
Topics: Amiodarone; Benzofurans; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; | 1986 |
Amiodarone as a cause of electrocardiographic changes simulating myocardial ischemia or subendocardial infarction.
Topics: Amiodarone; Coronary Disease; Diagnosis, Differential; Electrocardiography; Female; Heart; Humans; M | 1986 |
Medical and surgical treatment of sustained and recurrent post-infarction ventricular tachycardia.
Topics: Adult; Aged; Amiodarone; Benzofurans; Combined Modality Therapy; Endocardium; Female; Humans; Male; | 1985 |
Pharmacokinetics, antiarrhythmic effects, and tissue concentrations of amiodarone and desethylamiodarone in dogs with acute coronary artery occlusion.
Topics: Amiodarone; Animals; Arrhythmias, Cardiac; Benzofurans; Biotransformation; Chromatography, High Pres | 1985 |
Intravenous amiodarone in the treatment of refractory life-threatening cardiac arrhythmias in the critically ill patient.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Blood Pressure; Dopamine; Electrocardiog | 1986 |
[Sustained ventricular tachycardia in postinfarct ischemic heart disease: spontaneous polymorphism. Clinical, therapeutic and prognostic aspects].
Topics: Adult; Aged; Amiodarone; Coronary Disease; Electrocardiography; Female; Heart Ventricles; Humans; Ma | 1985 |
Amiodarone and sustained ventricular arrhythmias: statistical evidence of drug effectiveness.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Benzofurans; Cardiomyopathies; Coronary Disease; Drug Resi | 1985 |